BEST POSTERS

F23

Pressurized intraperitoneal aerosol chemotherapy (PIPAC) before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for nonresectable peritoneal metastasis.

M. Alyami, F. Mercier, M. Siebert, P.E. Bonnot, I. Bonnefoy, L. Villeneuve, N. Bakrin, O. Glehen (France)

G03

Preservation of fertility and ovarian function in young women undergoing HIPEC.

I. Sourrouille, C. Tantardini, P. Dartigues, V. Boige, A. Maulard, D. Elias, C. Poirot, D. Goéré (France)

E15

Hyperthermic intraperitoneal chemotherapy in stage IIIC and iv clinical stage ovarian carcinoma during interval laparotomy. phase II study. interim analysis of morbility and perioperative mortality.

R. Salcedo-Hernández, L. Cetina, D. Cantú-De-León, V. Córdoba, R. Tiznado, D. Isla-Ortiz, D. Gallardo-Rincón, Á. Herrera-Gómez (Mexico)

C74

Quality of primary surgical resection is a critical prognostic factor in patients with cytoreductive surgery and HIPEC for peritoneal carcinomatosis from colorectal cancer.

M. Ströhlein, S. Seefeldt, P. Thomaidis, M. Heiss (Germany)

C62

Prospective comparative analysis of complete total parietal peritonectomy v/s selective peritonectomy with crs + hipec in peritoneal surface malignancy - indian society of peritoneal surface malignancy (ISPSM) collaborative group study.

S.P. Somashekar, C. Rohit Kumar, S. Zaveri, K.R. Ashwin, Y. Ramya, A. Rauthan, V. Ahuja (India)

C33

Intraoperative packed red blood cell transfusion (IPRBT) and IPRBT to PCI ratio negatively affect outcomes of patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy – an analysis of 880 patients.

O.M. Fisher, N. Alzahrani, M. Kozman, A. Mohammad, S. Valle, W. Liauw, D. Morris (Australia)

C152

Epidemiology and survival impact of synchronous peritoneal metastases of epithelial malignancies: a nationwide population-based observational study.

K. Rovers, P. Vissers, L. Vaartjes, T. Van Oudheusden, W. Van Driel, J. De Wilt, J. Burger, P. Tanis, N. Kok, V. Lemmens, I. De Hingh (Netherlands)

C132

The cumulative incidence of metachronous peritoneal metastases of UICC II/III PT4 colorectal cancer.

P. Schredl, A. Dinnewitzer, D. Neureiter, S. Ciftci, J. Holzinger, J. Presl, K. Emmanuel, T. Jäger (Austria)

C119

Failure to return to intended oncological treatment (RIOT) after HIPEC impairs prognosis in gastric peritoneal carcinomatosis- analysis of the big-renape group.

P.E. Bonnot, G. Passot, E. Decullier, F. Quenet, D. Goere, K. Abboud, M. Pocard, P. Meeus, J.M. Bereder, S. Msika, C. Arvieux, D. Pezet, P. Rat, R. Wernert, T. Courvoisier, N. Pirro, O. Glehen (France), F.J. Lacueva (Spain)

C140

Primary tumor location predicts colorectal carcinomatosis burden in patients undergoing cytoreductive surgery despite KRAS or LVI status.

K. Lafaro, O. Eng, A. Blakely, M. Raoof, B. Lee (USA)

C15

Feasibility, safety, tolerability, and preliminary efficacy of repetitive laparoscopic epipac with oxaliplatin for isolated unresectable colorectal peritoneal metastases: preliminary results of a multicentre, single-arm phase ii study.

K. Rovers, R. Lurvink, E. Wassenaar, R. Wiezer, D. Boerma, J. Nederend, G.J. Creemers, S. Nienhuijs, I. De Hingh (Netherlands)

C145

Surgery and empathy: two sides of an optimized treatment of patients with peritoneal diseases.

L. Robieux, F. Zenasni, C. Flahault, M. Pocard, C. Eveno (France)

A25

Failure-to-rescue following cytoreductive surgery and hipec is determined by the type of complication – a retrospective study from the indian HIPEC registry.

A. Bhatt, S. Sinukumar, P. Kammer, S. Zaveri, F. Rajan, D. Damodaran, S. Mehta, H. Raj, N. Katdare, K. Sethna, M. Patel, R. Seshadri (India)

J4

Stapled versus hand-sewn intestinal anastomosis in patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC).

D. Cox, K. Robinson, S. Rafeeq, O. Shayeb, K. Hess, P. Mansfield, R. Royal, K. Fournier (USA)

C124

Two-stage cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei with high peritoneal carcinomatosis index.

L. Sidéris, B. Trilling, R. Hamad, P. Dubé, P. Richebe, A. Mitchell (Canada)

C92

Treatment of peritoneal dissemination in stomach cancer patients with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC): first results of the periscope i study.

R.T. Van Der Kaaij, E.C.E. Wassenaar, W.J. Koemans, K. Sikorska, H. Boot, C. Grootscholten, J.H.M. Schellens, M. Los, K.J. Hartemink, A.A.F.A. Veenhof, C.P. Hahn, A.P.I. Houwink, D. Boerma, B. Van Ramshorst, J.W. Van Sandick (Netherlands)

D18

Well differentiated papillary peritoneal mesothelioma- outcome analysis of to the psogi international registry.

M. Deraco, E. Nizri, O. Glehen, D. Baratti, J.J. Tuech, J.M. Bereder, V. Kepenekian, S. Kusamura, D. Goere (France)

H03

A comprehensive comparison of the five leading scoring systems for peritoneal carcinomatosis from colorectal origin to select CRS/HIPEC candidates with MRI.

M. Engbersen, I. Van 't Sant, J. Velzing, D. Lambregts, H. Van Eden, R. Beets-Tan, A. Aalbers, N. Kok, M. Lahaye (Netherlands)

A11

« Nobody tells you how to carry on living after you have won the fight" - interviews with cancer patients.

B. Lieske (Singapore), S. Schuele (Germany), A. Severin (Germany)

C150

Effects of neoadjuvant intraperitoneal/systemic chemotherapy (NIPS) on peritoneal metastasis and lymph node metastasis of gastric cancer.

Y. Yonemura (Japan)

C134

Peritoneal surface calculator (pesuca): a tool to quantify the resected peritoneal surface area after cytoreductive surgery.

T. Jäger, A. Dinnewitzer, P. Schredl, D. Neureiter, M. Fallaha, S. Ciftci, T. Kiesslich, K. Emmanuel (Austria)

E28

Recurrent ovarian cancer treated with radical cytorreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) : 122 consecutive pacients. Catalonian peritoneal carcinomatosis program.

D. Sabia, O. Crusellas Maña, I. Ramos Bernadó, M. Martín Baranera, P. Barrios Sanchez (Spain)

C73

Preoperative systemic chemotherapy in patients with PMCA of appendiceal origin treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

P. Ledakis, M.C. King, C. Munoz, V. Gushchin, M. Sittig, A. Sardi (USA)

E10

The role of small bowel PCI (SB-PCI) in patients with peritoneal metastasis from ovarian cancer: a new prognostic factor?

J. Spiliotis, A. Terras, N. Kopanakis, A. Prodromidou, M. Ferfelis, E. Efstathiou (Greece)

ANESTHESIA / EARLY RECOVERY / PREOPERATIVE PREPARATION / NUTRITION

A01

A prospective audit of perioperative hemodynamic variables in cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).

S. Patel, S. Solanki (India)

A02

PIPAC – anaesthesia considerations for a novel approach to chemotherapy.

V. Shree, T.J. Lim (Singapore)

A03

The impact of postoperative mechanical ventilation on outcome after cytoreduction and hyperthermic intraperitoneal chemotherapy.

J. Deneve, X. Huang, P. Hewgley, P. Dickson, E. Glazer, L. Douthitt, B. Bicknell, K. Pointer (USA)

A04

Perioperative impact of goal directed fluid therapy after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

J. Deneve, P. Hewgley, P. Dickson, E. Glazer, L. Douthitt, B. Bicknell, K. Pointer, J. Marler, E. Davidson, X. Huang, W. Guerrero, Z. Stiles (USA)

A05

Dose dependent effect of red blood cells transfusion on perioperative and long term outcomes in peritoneal surface malignancies treated with cytoreduction and HIPEC.

E. Nizri (Israel), S. Kusamura, G. Fallabrino, M. Guaglio, D. Baratti, M. Deraco (Italy)

A06

No need for postopertive icu-tailored perioperative care for the HIPEC patient.

M.L. Lindqvist, S.W. Wagmo (Sweden)

A07

Anaesthetic management of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy – developments leading to a reduction in mortality and morbidity rates.

N. Ashraf-Kashani, J. Bell (UK)

A08

Outcomes in patients on home parenteral nutrition with intestinal failure secondary to advanced peritoneal malignancy.

A. Yates, D. Swain, S. Tierney, L. Taylor, S. Muirden (UK)

A09

Phase II randomized study on tissue uptake and pharmacokinetics of cisplatin according to different intra abdominal pressures during HIPEC NCT02949791.

S. Kusamura, L. Fumagalli, G. Garrone, A. Cavalleri, F. Barretta, D. Baratti, M. Guaglio, M. Deraco (Italy)

A10

Fast – track perioperative management in patients undergoing cytoreductive surgery and hyperthermic intraoperitoneal chemotherapy.

V. Kalles, I. Kyriazanos, T. Metaxas, D. Farmakis, M. Marougkas, M. Ferfelis, N. Bakouras, M. Gkiaourakis, O. Chalkidis, P. Koustas, A. Ntinas, E. Chatzopoulos, J. Spiliotis (Greece)

A11

« Nobody tells you how to carry on living after you have won the fight » - interviews with cancer patients.

B. Lieske (Singapore), S. Schuele (Germany), A. Severin (Germany)

A12

Risk factors associated with wound complications after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).

N. Chandran, G. Tan, M. Teo, C. Chia (Singapore)

A13

Perioperative anaesthetic management for cytoreductive surgery and heated intraperitoneal chemotherapy: influence on morbidity and mortality in peritoneal tumours. a single centre experience.

V. Kasipandian, S.T. o'dwyer, P. Chalakova (UK)

A14

The effect of intraoperative fluid administration on outcomes of patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.

R. Shamavonian, R. Mclachlan, O. Fisher, N. Alzahrani, S. Valle, W. Liauw, D. Morris (Australia)

A15

Implementation of an enhanced recovery program after complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: can it be applicable and is it efficient?

J.B. Delhorme, D. Charleux-Muller, T. Fabacher, B. Romain, E. Triki, J.P. Steinmetz, C. Wollbrett, N. Meyer, S. Rohr, C. Brigand (France)

A16

Predictive factors for fast and uncomplicated postoperative course in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy – a single center experience.

A. Brandl, M. Alberto, W. Raue, V. Müller, J. Pratschke, B. Rau (Germany)

A17

Goal-directed therapy in cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.

N. Esteve Pérez, A. Ferrer-Robles, G. Gómez-Romero, M. Verd-Rodriguez, D. Fabián-Gonzalez, L.C. Mora-Fernández, J.J. Segura-Sanpedro, R. Morales-Soriano (Spain)

A18

Early identification of psychological risk - pre-operative psychological screening in peritoneal malignancy patients: a service evaluation.

Z. Tebbs, N. Vanderpuye (UK)

A19

Variations in intraoperative fluid administration during cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.

R. Mclachlan, R. Shamavonian, O. Fisher, N. Alzahrani, S. Valle, W. Liauw, D. Morris (Australia)

A20

Towards a specific quality of life scale for peritoneal surface malignancies: insights from pakistan.

R.H. Sayyed (Pakistan), S.K. Niazi (Pakistan), S. Zehra (UK), H. Aleezay (Pakistan), F. Khan (Pakistan)

A21

Enhanced recovery after surgery (ERAS) protocol implementation for cytoreductive surgery (CS) with heated intraperitoneal chemotherapy (HIPEC).

E. Samlowski, S. Aurit, G. Plitt, M. Reisbig, B. Loggie (USA)

A22

Utility of BIPAP (biphasic positive airway pressure) ventilation in CRS + HIPEC (cytoreductive surgery + hyperthermic intraperiotneal chemotherapy).

P. Kammar, S. Waghoo, J. Anam, D. Agarwal, N. Borkar, S. Mehta, S. Purohit, N. Kaul (India)

A23

Pre-admission psychological management of pseudomyxoma peritonei patients – a service evaluation.

N. Vanderpuye, R. Boyle (UK)

A24

Intraoperative fluid administration patterns during cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for patients with high volume peritoneal disease.

R. Mclachlan, R. Shamavonian, O. Fisher, N. Alzahrani, S. Valle, D. Morris (Australia)

A25

Failure-to-rescue following cytoreductive surgery and hipec is determined by the type of complication – a retrospective study from the indian HIPEC registry.

A. Bhatt, S. Sinukumar, P. Kammer, S. Zaveri, F. Rajan, D. Damodaran, S. Mehta, H. Raj, N. Katdare, K. Sethna, M. Patel, R. Seshadri (India)

A26

Management of hyperglycaemia during oxaliplatin hyperthermic intra-peritoneal chemotherapy: audit results.

V. Kasipandian, C. Higham, L. Hopewell (UK)

A27

Low rate of intraoperative and postoperative blood transfusion in cytoreductive surgery and HIPEC: is this possible at the beginning of the experience?

A. Petruzziello, W.A. Casteleins, V.M. Haida, M.C. Magalhães (Brazil)

A28

Extended use thoracic epidurals in cytoreductive surgery.

N. Ashraf-Kashani, S. Shankar, S. Allen, J. Bell (UK)

A29

Perioperative management in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a 2 year retrospective study.

D. Rodrigues, M. Silva, R. Silva, M. Fortunato, C. Fernandes, R. Bessa Melo (Portugal)

A30

Anesthetic approach in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: 7 year retrospective study in a portuguese single center.

M. Silva, R. Silva, D. Rodrigues, M. Fortunato, R. Bessa Melo, C. Fernandes (Portugal)

A31

Pain control in peritonectomy and hyperthermic intraperitoneal chemotherapy: a 2 year retrospective study.

M. Silva, D. Rodrigues, R. Silva, M. Fortunato (Portugal)

A32

Bundled care to reduce surgical site infections after cytoreductive surgery and HIPEC.

E. Poli, M. Millis, S. Sherman, F. Dahdaleh, A. Kamm, K. Turaga (USA)

A33

Effect of enhanced recovery after surgery (ERAS) program implementation among patients undergoing cytoreductive surgery, hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) in a tertiary hospital in the philippines.

E.J. Castro, M.P. Lopez (Philippines)

A34

Reasons for hospital readmission following cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC).

K. Robinson, K. Fournier, D. Cox, S. Rafeeq, O. Shayeb, A. Arrington, T. Wray, P. Mansfield, R. Royal (USA)

A35

A strategy to avoid potential problems in the initial learning-curve in hipec : hemodynamic monitoring and goal directed fluid therapy

A. Petruzziello, W.A. Casteleins, V.M. Haida, J.M. Nardin, M.C. Figueroa-Magalhaes, B. Martins-Camara, J. Silva Motta (Brazil)

A36

Fluid optimal strategy during cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)

M.A. Millis, E.C. Poli, S.K. Sherman, F.S. Dahdaleh, A. Kamm, K.K. Turaga (USA)

CLINICAL CASES

B01

Cytoreductive surgery and HIPEC for primary peritoneal anaplastic ependymoma with extensive peritoneal carcinomatosis.

S.J. Chang, J.H. Son, T.W. Kong, H.S. Ryu (Korea)

B02

CRS and HIPEC in «non-standard» cancers treatment.

T. Jastrzebski, W. Polkowski, M. Bebenek, T. Polec, J. Mielko, B. Kapturkiewicz (Poland)

B03

Surviving with unresected peritoneal metastasis from rectal cancer beyond 7 years.

J.S. Wong, C. Siew, T. Ho (Singapore)

B04

Combined treatment of neaodjuvant chemotherapy, surgical resection and hyperthermic intraperitoneal chemotherapy for pancreatic adenocarcinoma presenting with peritoneal carcinomatosis

E. Fernandez-Sevilla, P. Tortajada, J.J. Tuech, L. Schwarz (France).

B05

Routine use of large tube drains post HIPEC

W.H. Sim, T.W.T. Ho, J.S.H. Wong, C.C.H. Siew (Singapore).

B06

Pathological complete response to chemotherapy in metachronous colorectal peritoneal carcinomatosis

C. Siew, J. Wong, T. Ho (Singapore).

B07

Peritoneal pseudomyxomas arising in mature teratomas treated with cytoreduction and HIPEC. Report of 4 cases.

R. Salcedo-Hernández, M.D. Pérez-Montiel, S. Barquet-Muñoz, V. Córdoba, L. Lino-Silva (Mexico)

B08

Cytoreductive surgery and laparoscopy-enhanced HIPEC for peritoneal dissemination of pleural mesothelioma.

M. Lotti, M. Marini, N.E. Allievi, E. Poiasina, G. Panyor, M. Giulii Capponi, C. Bertani, E.M. Vaterlini (Italy)

B09

Current status of clinical trials in CRS and HIPEC: where do we stand?

W. Morano, M. Khalili, D. Chi, J. Esquivel, W. Bowne (USA)

B10

Recurrence after 30 years disease free survival of a multicystic peritoneal mesothelioma.

J. Coget, L. Schwarz, E. Fernandez De Sevilla, J.C. Sabourin, J.J. Tuech (France)

B11

Which treatment for locally advanced rectal carcinoma with peritoneal metastasis? Feasibility of total pelvic exenteration associed with hyperthermic intraperitoneal chemotherapy.

J. Coget, L. Schwarz, E. Fernandez De Sevilla, J.J. Tuech (France)

B12

Primary peritoneal hepatoid carcinoma - case report.

E. Akaishi, M. Arakaki, F. Costa, I. Galindo, E. Silva, H. Lima, N. Mizumoto, E. Utiyama (Brazil)

B13

Early and long-term outcome data of patients with peritoneal surface malignancies treated by surgery and hyperthermic intraoperative intraperitoneal chemotherapy from single center experience from turkey.

E. Canbay, B. Canbay Torun, S. Saglam, C. Sezgin, C. Altunal, S. Koc (Turkey), Y. Yonemura (Japan)

B14

Perforated mucocele of the appendix in LUQ; a challenging anatomical abnormality and an improvised surgical technique.

T. Bin Traiki, B. Alhassan (Saudi Arabia)

B15

Response to laparascopic HIPEC as an induction chemotherapy in patients with unresectable peritoneal surface malignancies.

E. Canbay, B. Canbay Torun, S. Saglam, C. Sezgin (Turkey), Y. Yonemura (Japan)

B16

Late, rarely reported skin complication after the use of hyperthermic intraperitoneal chemotherapy in a female patient.

K. Beaty, R. Royal, P. Mansfield, K. Fournier (USA)

B17

Peritoneal mucinous carcinomatosis with unknown primary site- a report of clinical presentation and outcomes in 4 cases.

S. Mishra, I. Gorur, S. Sheth, L. Parikh, A. Bhatt (India)

B18

Recurrent peritoneal carcinomatosis and repeated cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC): 2 cases report.

P. Muñoz, L.D. Juez, S. Corral, M. Cuadrado, J. Cabañas, J. Galindo (Spain)

B19

Indications of CRS and HIPEC in the management of patients with peritoneal metastasis and multiple primaries.

P. Muñoz, L.D. Juez, M. Cuadrado, R. Ferreiro, J. Cabañas, J. Galindo (Spain)

B20

HIPEC in young and older patient in Mexico.

G. Flores Ayala, J.C. Vázquez Limón, M. García Soto (Mexico)

B21

Prognostic implications of small bowel involvement in patients with peritoneal metastasis after cytoreductive surgery and heated intraperitoneal chemotherapy.

H. Halabi, A. Yahanda, J. Ai, H. Huss, K. Brown (USA)

B22

Thoracoabdominal fistula: a life-threatening complication after complex CRS & HIPEC.

F. Regueira, P. Marti, G. Zozaya, R. Calderon, A. Chopitea, L. Granero, C. Tuero, J.L. Hernández-Lizoain (Spain)

B23

Predictive role of neutrophil to lymphocyte ratio on survival for patients with peritoneal carcinomatosis underwent cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

H.C. Hung, T.J. Chang, H.H. Chou, C.W. Lee, J.F. You, M.C. Yu, C.H. Lai, Y.J. Hsu, T.J. Wu (Taiwan, Republic of China)

B24

Multidisciplinary approach on cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis: preliminary 3 years results at a single institution.

T.J. Wu, H.C. Hung, C.W. Lee, M.C. Yu, T.C. Chang, H.H. Chou, C.H. Lai, J.G. Hung, J.F. You, Y.J. Hsu (Taiwan, Republic of China)

B25

Providing standard of care to patients with peritoneal surface malignancies in a developing country: our journey in pakistan.

R.H. Sayyed, S.K. Niazi, F. Khan, M. Raza, S. Rashid, M.S. Amanullah, A.A. Jafri, F. Qureshi, T. Siddiqui (Pakistan)

COLORECTAL / GASTRIC / OTHERS DIGESTIVE PERITONEAL METASTASES

C01

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy combined with liver resection for concurrent peritoneal carcinomatosis and hepatic metastasis of gastrointestinal and gynecological primary tumors.

P. Horvath, S. Beckert, F. Struller, A. Koenigsrainer, I. Koenigsrainer (Germany)

C02

Can machine learning predict resecability of a peritoneal carcinomatosis ?

A. Maubert, L. Birtwisle, J.L. Bernard, E. Benizri, J.M. Bereder (France)

C03

LGR5 expression predicts peritoneal recurrence after complete resection of primary colon cancer.

H. Nagata, S. Ishihara, T. Tanaka, K. Hata, K. Kawai, H. Nozawa (Japan)

C04

Intraperitoneal chemotherapy with paclitaxel and s-1 plus oxaliplatin for gastric cancer with peritoneal metastasis.

H. Yamaguchi, H. Ishigami, R. Kanamaru, H. Ohzawa, S. Matsumoto, K. Kurashina, Y. Haruta, Y. Hosoya, H. Fujii, N. Sata, J. Kitayama (Japan)

C05

Increased Prevalence of Second Primary Cancers in Patients with Appendiceal Adenocarcinoma.

N. Pozzi, M. Cahan, B. Switzer, L. Lambert (USA)

C06

Breast cancer peritoneal metastasis-role of cytoreductive surgery & HIPEC.

J. Spiliotis, A. Prodromidou, D. Farmakis, T. Metaxas, A. Ntinas, P. Koustas, H. Chalkidis, A. Christopoulou (Greece)

C07

Cytoreduction surgery with hyperthermic intraperitoneal chemotherapy: appraisal of outcomes in a newly emerging algerian center.

M.A. Abid (Algeria)

C08

Neoadjuvant chemotherapy followed by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer: a feasibility and safety study.

M. Leimkühler, P.H. Hemmer, A.K. Reyners, D.J. De Groot, R.J. Van Ginkel, L.B. Been, G.H. De Bock, B.L. Van Leeuwen (Netherlands)

C09

Strategies for managing intraoperative discovery of limited colorectal peritoneal metastases.

A. Mariani, M. Gelli, I. Sourrouille, L. Benhaim, M. Faron, C. Honoré, D. Elias, D. Goéré (France)

C10

Cytoreduction surgery with hyperthermic intraperitoneal chemotherapy in metastatic peritoneal hepatocellular carcinoma with high PCI.

K.C. Hung, Y.Y. Wang, G.C. Huang, Y.F. Chen (Taiwan, Republic of China)

C11

Risk factors for morbidity, mortality and prolonged length of stay after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

M. Bailon-Cuadrado, E. Asensio-Diaz, B. Perez-Saborido, P. Pinto-Fuentes, I. Gonzalez-Blanco, D. Pacheco-Sanchez (Spain

C12

Hyperthermic intraperitoneal chemotherapy (HIPEC) in combined treatment of locally advanced and intraperitonealy disseminated gastric cancer: a retrospective cooperative central-eastern european study.

R. Yarema (Ukraine), J. Mielko (Poland), T. Fetsych (Ukraine), M. Ohorchak (Ukraine), K. Rawicz-Pruszynski (Poland), T. Jastrzebski (Poland), P. Hyrya, Y. Kovalchuk, V. Safiyan, I. Karelin, A. Mashukov, V. Maksimovsky, V. Kopetskiy, Y. Kondratskiy (Ukraine), M. Paskonis (Lituania), W. Polkowski (Poland)

C13

Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy in treating patients with peritoneal carcinomatosis: the greek experience.

J. Spiliotis, N. Kopanakis, A. Terras, A. Prodromidou, M. Ferfelis, A. Raptis, N. Zampitis, I. Kyriazanos, A. Christopoulou, E. Efstathiou (Greece)

C14

The role of chemotherapy in the setting of resectable peritoneal carcinomatosis of colorectal origin.

G. Liberale, A. Hendlisz (Belgium)

C15

Feasibility, safety, tolerability, and preliminary efficacy of repetitive laparoscopic epipac with oxaliplatin for isolated unresectable colorectal peritoneal metastases: preliminary results of a multicentre, single-arm phase ii study.

K. Rovers, R. Lurvink, E. Wassenaar, R. Wiezer, D. Boerma, J. Nederend, G.J. Creemers, S. Nienhuijs, I. De Hingh (Netherlands)

C16

Differences between peritoneal metastases and local recurrence from colorectal cancers after cytoreductive surgery and HIPEC.

F. Dumont, S. Joseph, G. Lorimier, V. De Franco, R. Werner, V. Verriele, O. Kerdraon, J. Raimbourg, H. Senellart, O. Campion, O. Capitain, V. Guerin-Meyer, J.L. Raoul, S. Hiret, E. Thibaudeau (France)

C17

The current practice of cytoreductive surgery and hipec for colorectal peritoneal metastases: results of a worldwide web-based survey of the peritoneal surface oncology group international (PSOGI).

M. Bushati (Italy), K.P. Rovers (Holland), A. Sommariva (Italy), P.H. Sugarbaker (USA), D.L. Morris (Australia), Y. Yonemura (Japan), C.A. Quadros (Brazil), S.P. Somashekhar (India), W. Ceelen (Belgium), P. Dubé (Canada), Y. Li (China), V.J. Verwaal (Denmark), O. Glehen (France), P. Piso (Germany), J. Spiliotis (Greece), M.C.C. Teo (Singapore), S. González-Moreno (Spain), P.H. Cashin (Sweden), K. Lehmann (Switzerland), M. Deraco (Italy), B. Moran (UK), I.H.J.T. De Hingh (Holland)

C18

Can baseline quality of life scores predict for morbidity and survival after CRS and HIPEC: a prospective study.

C. Chia, G. Tan, J. Ong, C. Lim, M. Teo (Singapore)

C19

Intraperitoneal chemotherapy with paclitaxel for gastric cancer with peritoneal recurrence after gastrectomy.

D. Kobayashi, M. Kanda, C. Tanaka, M. Suenaga, H. Takami, N. Hattori, M. Hayashi, Y. Niwa, S. Yamada, G. Nakayama, M. Koike, M. Fujiwara, Y. Kodera (Japan)

C20

Patient selection policy and pattern of recurrence after cytoreductive curgery and HIPEC for colorectal carcinomatosis play a role on patients' outcome.

M. Vaira, M. Robella, A. Cinquegrana, G. Gavello, M. De Simone (Italy)

C21

HIPEC experience in a rural community hospital using modified perfusion system.

S. Saha, J. Edwards, A. Onitilo (USA)

C22

Synchronous peritoneal metastases of breast cancer origin: a population-based study on incidence, risk factors and survival.

M. Bushati (Italy), K.P. Rovers, L. De Munck, P.A.J. Vissers, S. Siesling, I.H.J.T. De Hingh (Netherlands)

C23

Sarcopenia is a predictive factor on morbidity and overall survival in patients with colorectal cancer peritoneal metastasis.

C. Agalar, S. Sokmen, N.C. Arslan, C. Altay, I. Basara, A.E. Canda, F. Obuz (Turkey)

C24

Artificial neural networks to predict outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a tool for patients selection.

M. Prodeau, V. Kepenekian, F. Mercier, F.R. Pruvot, P. Zerbib, O. Glehen, G. Passot (France)

C25

Multidisciplinary treatment combining gastrectomy with intraperitoneal and systemic chemotherapy for gastric cancer with peritoneal metastasis: a single center experience over 10 years.

H. Ishigami, H. Yamaguchi, H. Yamashita, M. Asakage, J. Kitayama (Japan)

C26

Gastrectomy after intraperitoneal plus systemic chemotherapy for gastric cancer patients with peritoneal metastasis or positive peritoneal cytology: analysis of 124 patients from four clinical trials.

M. Aizawa, H. Ishigami, T. Omori, Y. Kodera, R. Fukushima, M. Imano, T. Arigami, T. Tomita, K. Kishi, T. Matsumura, Y. Ito, Y. Hirono, Y. H, H. Yamaguchi, J. Kitayama (Japan)

C27

Cytoreductive surgery & hyperthermic intraperitoneal chemotherapy for synchronous versus metachronous colorectal peritoneal metastases.

J. Wong, G. Tan, W.Y. Ng, C. Chia, M. Teo (Singapore)

C28

Results of different treatment options for patients with gastric cancer with peritoneal metastases in 100 consecutive patients – a single center experience.

A. Brand, P. Thuss-Patience, W. Raue, J. Hartmann, M. Biebl, J. Pratschke, B. Rau (Germany)

C29

The use of small bowel pci score as a prognostic index in patients with peritoneal carcinomatosis secondary to colorectal cancer.

J. Spiliotis, V. Kalles, I. Kyriazanos, N. Kopanakis, A. Terra, E. Efstathiou, A. Prodromidou, A. Christopoulou (Greece)

C30

Analysis of re-hipec for recurrent peritoneal carcinomatosis confined to the abdominal wal.

E. Boldo, E. Fernandez, A. Mayol, R. Lozoya, S. Jareño, J.C. Pastor, A. Coret, D. Escribano, C. Martinez, C. Dehevia, C. Fortea, G. Perez De Lucia (Spain)

C31

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal malignancies at the national cancer centre singapore.

G. Tan, C. Chia, W.Y. Ng, J. Ong, K.C. Soo, M. Teo (Singapore)

C32

Analysis of morbidity associated with abdominal wall resection and reconstruction after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC).

R. Parikh, S. Shah, V. Dhurandhar, N. Alzahrani, D. Morris (Australia)

C33

Intraoperative packed red blood cell transfusion (IPRBT) and IPRBT to PCI ratio negatively affect outcomes of patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy – an analysis of 880 patients.

O.M. Fisher, N. Alzahrani, M. Kozman, A. Mohammad, S. Valle, W. Liauw, D. Morris (Australia)

C34

The impact of gastrectomies on patients requiring cytoreductive surgery and heated intraperitoneal chemotherapy for advanced lower gastrointestinal malignancies – a propensity-score matched analysis.

O.M. Fisher, J. Lansom, M. Kozman, M. Alshahrani, S. Valle, N. Alzahrani, W. Liauw, D. Morris (Australia)

C35

Soft tumour consistency and use of 5-fu epic are both associated with improved survival in appendiceal adenocarcinoma following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy short title: tumour texture and appendix cancer.

Y. Huang, N. Alzahrani, O. Fisher, T. Chua, M. Kozman, W. Liauw, A. Arief, S. Valle, D. Morris (Australia)

C36

Early postoperative intraperitoneal chemotherapy is associated with survival benefit for appendiceal adenocarcinoma with peritoneal dissemination.

D. Morris, Y. Huang, N. Alzahrani, W. Liauw (Australia)

C37

Early postoperative intraperitoneal chemotherapy for low-grade appendiceal mucinous neoplasms with pseudomyxoma peritonei- is it beneficial?

Y. Huang, N. Alzahrani, W. Liauw, D. Morris (Australia)

C38

What is the clinical impact of nodal status on survival after complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for patients with gastric peritoneal metastasis?

P.E. Bonnot, D. Vaudoyer, F. Mercier, K. Abboud, L. Villeneuve, J.M. Bereder, F. Quenet, D. Goere, P. Meeus, S. Msika, C. Arvieux, J. Lefevre, D. Pezet, R. Wernert, P. Rat, N. Pirro, T. Courvoisier, R. Kianmanesh, F. Marchal, M. Pocard, O. Glehen (France)

C39

Is cytoreductive surgery and hyperthermic intraperitonealchemotherapy reasonable treatment for gastric signet-ring cell adenocarcinoma and linitis plastica with peritoneal metastasis? cyto-chip study—ancillary results.

P.E. Bonnot, G. Piessen, F. Mercier, E. Decullier, M. Pocard, B. Meunier, J.M. Béréder, K. Abboud, F. Marchal, F. Quenet, D. Goere, C. Arvieux, S. Msika, D. Pezet, N. Pirro, P. Rat, R. Wernert, J. Lefevre, T. Courvoisier, P. Meeus, O. Glehen (France)

C40

Peritoneal carcinomatosis of mixed adenoendocrine carcinoma treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC): an international registry.

F. Mercier (France), P. Cashin (Sweden), W. Ceelen (Belgium), P.E. Bonnot (France), L. Villeneuve (France), G. Passot (France), E. Levine (USA), O. Glehen (France)

C41

Prognostic importance of genetic alterations in colorectal peritoneal metastases.

H. Birgisson, M. Enblad, W. Graf, A. Terman, P. Pucholt, B. Viklund, A. Isaksson (Sweden)

C42

Comparison between PCI and dutch region count as a prognostic tool in patients with colorectal peritoneal metastases.

W. Van Eden, F. Verheij, N. Kok, A. Aalbers (Netherlands)

C43

The volume time index (VTI): the ratio of peritoneal cancer index to time from primary tumour resection is a prognostic surrogate of tumour aggressiveness and biology in patients with colorectal cancer with peritoneal metastases undergoing cytoreductive surgery and intraperitoneal chemotherapy.

M.A. Kozman, O.M. Fisher, S.J. Valle, N. Alzahrani, W. Liauw, D.L. Morris, R. Shamavonian (Australia)

C44

Cea to peritoneal carcinomatosis index (PCI) ratio is prognostic in patients with colorectal cancer peritoneal carcinomatosis undergoing cytoreduction surgery and intraperitoneal chemotherapy.

R. Shamavonian, M.A. Kozman, O.M. Fisher, B.J. Rebolledo, R. Parikh, S.J. Valle, N.A. Alzahrani, W.L. Liauw, D.L. Morris (Australia)

C45

Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy for colorectal or appendiceal peritoneal metastasis.

Y. Gohda, K. Deguchi, Y. Nagai, A. Kataoka, K. Ohtani, T. Kiyomatsu, N. Kokudo, H. Yano (Japan)

C46

The short-term oncologic outcomes of hyperthermic intraperitoneal chemotherapy (HIPEC) after cytoreductive surgery to treat peritoneal carcinomatosis from colorectal cancer: a prospective study of a tertiary referral center in south korea.

E.J. Park, Y. Jeon, J. Kang, S.H. Baik (Korea)

C47

Involvement of the right upper quadrant is predictive of an inferior survival in patients with colorectal pm undergoing complete cytoreductive surgery and hipec – a retrospective study from the indian HIPEC registry.

A. Bhatt, S. Mehta, S. Zaveri, M. Ray, P. Kammer, D. Damodaran, S. Sinukumar, R. Seshadri (India)

C48

HIPEC with gemcitabine as an adjuvant locoregional treatment after radical surgery in pancreatic cancer. presentation of the clinical trial n-2016-004298-41.

E.P. García Santos, D. Padilla Valverde, P. Villarejo Campos, S. Sánchez García, J. Martín Fernández (Spain)

C49

Morbimortality of patients undergoing citoreduction + closed HIPEC with CO2 agitation system: a multicentre study.

A. Gutierrez, R. Gomez, A. Lopez, S. Sanchez, P. Villarejo, D. Padilla, I. Manzanedo, F. Pereira, E. Perez-Viejo, L. Gonzalez, E. Lopez-Tomassetti, J.R. Hernandez, E. Diaz, I. Fabra, A. Titos, M. Pitarch, F. Ochando, F.J. La Cueva (Spain)

C50

Biomarker concordance between primary colorectal cancer and peritoneal metastases.

D. Bhullar, S. O'dwyer, O. Aziz (UK)

C51

Exosomal microrna profiles in peritoneal fluids as a therapeutic biomarker for peritoneal metastasis of gastric cancer.

H. Ohzawa, Y. Kumagai, H. Yamaguchi, Y. Hosoya, N. Sata, J. Kitayama (Japan)

C52

Generation and validation of an immunohistochemical panel to predict chemosensitivity and prognosis in patients with colorectal peritoneal carcinomatosis.

J.W.S. Tan, N.B. Shannon, H.L. Tan, X. Qiu, J. Hendrikson, W.H. Ng, C.S. Chia, G.H.C. Tan, K.C. Soo, O.L. Kon, C.A.J. Ong, M.C.C. Teo (Singapore)

C53

A mouse model of colorectal peritoneal carcinomatosis driven by paracrine signalling provides a unique opportunity for drug testing.

W.H. Ng, J. Hendrikson, X. Qiu, J.W.S. Tan, N.B. Shannon, C.S. Chia, G.H.C. Tan, K.C. Soo, O.L. Kon, C.A.J. Ong, M.C.C. Teo (Singapore)

C54

Clinicopathological differences among colorectal cancer patients with different sites of metastasis.

N. Chandran, G. Tan, M. Teo, C. Chia (Singapore)

C55

Postoperative abdominal infections after resection of t4 colon cancer increase the risk of intra-abdominal recurrence.

C. Klaver, K. Wasmann, M. Verstegen, J. De Wilt, I. Nagtegaal, J. Van Der Bilt, P. Tanis, B. Van Ramshorst, H. Van Santvoort, (Netherlands) A. Wolthuis, A. D'hoore (Belgium)

C56

Intraperitoneal and systemic chemotherapy for gastric cancer with peritoneal metastases.

J.B.Y. So, D.Y.S. Chan, N.L.X. Syn, R. Yap, C.T. Neogh, J.N.S. Phua, E. Chen, J.S. Ho, H.L. Tan, N.Y.L. Ngoi, R. Sundar, C.S. Tan, C.E. Chee, A. Shabbir, W.P. Yong (Singapore)

C57

Oncologic results of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for gastric cancer with peritoneal carcinomatosis: multicenter study of spanish group of peritoneal cancer surgery (GECOP).

I. Manzanedo, F. Pereira, A. Gutiérrez-Calvo, R. Gómez-Sanz, F. Martínez-Regueira, G. Zozaya, Á. Casado-Adam, Á. Arjona, P. Cascales-Campos, J. Gil, X. Arteaga, A. García-Fadrique, Á. Serrano, E. Pérez-Viejo, A. López-García (Spain)

C58

Cytoreductive surgery versus cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for small bowel neuroendocrine tumor with peritoneal metastasis.

F. Mercier, A. Pasquer, M. Gelli, E. Levine, L. Villeneuve, G. Poncet, T. Walter, O. Glehen (France)

C59

Results of curative strategy in patients with peritoneal and extraperitoneal metastases from colorectal cancer.

I. Sourrouille, S. Derieux, M. Gelli, L. Benhaim, A. Mariani, M. Faron, C. Honoré, D. Elias, D. Goéré (France)

C60

Two regimens of intraperitoneal chemotherapy after cytoreductive surgery improved survival of patients with colorectal peritoneal metastases.

S.Y. Park, J.S. Park, H.J. Kim, G.S. Choi, I.T. Woo (Korea)

C62

Prospective comparative analysis of complete total parietal peritonectomy v/s selective peritonectomy with crs + hipec in peritoneal surface malignancy - indian society of peritoneal surface malignancy (ISPSM) collaborative group study.

S.P. Somashekar, C. Rohit Kumar, S. Zaveri, K.R. Ashwin, Y. Ramya, A. Rauthan, V. Ahuja (India)

C63

Surgihoney reactive oxygen in the management of wounds following cytoreductive surgery and HIPEC.

A. Pcolkins, A. Brandl, N. Battersby, M. Dryden, S. Nunn, F. Mohamed, S. Dayal, T. Cecil, B. Moran (UK)

C64

Outcomes after laparoscopic cytoreductive surgery in patients with limited peritoneal metastasis of colorectal cancer.

S.Y. Park, J.S. Park, H.J. Kim, G.S. Choi, I.T. Woo, I.K. Park (Korea)

C65

Incidence and risk factors of neutropenia after intraperitoneal chemotherapy for advanced colorectal cancer.

S.Y. Park, J.S. Park, H.J. Kim, I.T. Woo, I.K. Park, G.S. Choi, J.G. Kim, B.W. Kang (Korea)

C66

Chemotherapy drugs versus postoperative morbidty in hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancies: indian society for peritoneal surface malignancy collaboration study.

A. Kr, S. Sp, S. Zaveri S, R. Kumar, R. Yetahdka, A. Rauthan (India)

C67

Delta peritoneal cancer index (PCI): a new dynamic prognostic parameter for survival in patients with peritoneal carcinomatosis from colorectal cancer.

J. Hentzen, W. Van Der Plas, H. Kuipers, S. Ramcharan, L. Been, F. Hoogwater, R. Van Ginkel, G. Van Dam, P. Hemmer, S. Kruijff (Netherlands)

C68

The impact of synchronous versus metachronous peritonitis carcinomatosa on overall- and disease-free survival in colorectal patients scheduled for.

J. Hentzen, K. Rovers, H. Kuipers, W. Van Der Plas, L. Been, F. Hoogwater, R. Van Ginkel, G. Van Dam, P. Hemmer, I. De Hingh, S. Kruijff (Netherlands)

C69

Peritoneal and extraperitoneal relapse after previous curative treatment of peritoneal metastases from colorectal cancer: what survival can we expect?

M. Gelli, J.F.L. Huguenin, T. De Baere, L. Benhaim, A. Mariani, V. Boige, D. Malka, M. Ducreux, D. Elias, D. Goéré (France)

C70

Pathological n2 status is predictive of a high incidence of peritoneal metastases in patients undergoing curative surgical treatment for colorectal cancer- experience from an indian tertiary care institution.

R. Bhamre, A. Bhatt, J. Rohila, V. Kalikar, A. Desouza, A. Saklani (India)

C71

Impact of the pci on outcomes of cytoreductive surgery and hipec in patients with mucinous colorectal peritoneal metastases- a report from the indian hipec registry.

A. Bhatt, P. Kammer, S. Zaveri, D. Damodaran, M. Ray, N. Katdar, S. Sinukumar, R. Seshadri, S. Mehta (India)

C72

Assessing the heritage of peritoneal metastasis of colorectal origin: does the location of the initial primary tumour have an effect on the disease severity and the outcome of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy ?

Z.Z. Yong, G.H.C. Tan, M.C.C. Teo (Singapore)

C73

Preoperative systemic chemotherapy in patients with PMCA of appendiceal origin treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

P. Ledakis, M.C. King, C. Munoz, V. Gushchin, M. Sittig, A. Sardi (USA)

C74

Quality of primary surgical resection is a critical prognostic factor in patients with cytoreductive surgery and HIPEC for peritoneal carcinomatosis from colorectal cancer.

M. Ströhlein, S. Seefeldt, P. Thomaidis, M. Heiss (Germany)

C75

Bladder resection and HIPEC.

V. Verwaal (Denmark), K. Speeten (Belgique), I. De Hingh (Holland), S. S.p. (India), M. Møller (Denmark), D. Morris (Austria), A. Mehta (UK), O. Glehen (France), P. Sugarbaker (USA)

C76

Comparison of prognostic value of psogi and who pathologic classifications of patients with appendiceal mucinous neoplasms and associated pseudomyxoma peritonei.

S. Er, C. Yüksel, U.F. Turan, S. Özden, Ö. Yalkin, S. Güresci, M. Tez, A.E. Ünal (Turkey)

C77

Treatment and survival among danish patients with colorectal synchronous peritoneal metastases.

S. Ravn, C.F. Christiansen, U. Heide-Joergensen, R.H. Hagemann-Madsen, V.J. Verwaal, L.H. Iversen (Denmark)

C78

Risk factors for metachronous peritoneal metastases: a nationwide population-based cohort study of danish colorectal cancer patients.

S. Ravn, C.F. Christiansen, U. Heide-Joergensen, R.H. Hagemann-Ma, V.J. Verwaal, L.H. Iversen (Denmark)

C79

Incidence and prevalence of peritoneal metastases among danish patients with colorectal cancer.

S. Ravn, C.F. Christiansen, U. Heide-Jørgensen, R.H. Hageman-Madsen, V.J. Verwaal, L.H. Iversen (Denmark)

C80

Patient-reported outcomes supporting an individualized follow-up after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. a study protocol.

S. Ravn, H.V. Thaysen, L. Seibæk, L.H. Iversen (Denmark)

C81

Treatment pathways and outcome of patients with colorectal peritoneal metastasis at a national peritoneal tumour centre.

S. O'dwyer, A. Larentzakis, O. Aziz, C. Selvasekar, P. Fulford, A. Renehan, M. Wilson (UK)

C82

Predicting survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for appendix adenocarcinoma.

O. Aziz, I. Jaradat, B. Chakrabarty, C. Selvasekar, P. Fulford, M. Saunders, A. Renehan, M. Wilson, S. O'dwyer (UK)

C83

Impact of colorectal liver metastases volume on patients undergoing simultaneous liver resection in cytoreductive surgery with heated intraperitoneal chemotherapy.

T. Meares, C. Gauci, M. Bock, O. Fisher, N. Alzahrani, S. Valle, W. Liauw, D. Morris (Australia)

C84

An update on the incidence, risk factors, management and clinical sequalae of postoperative pancreatic fistula following cytoreductive surgery and HIPEC.

C. Gauci, T. Meares, O. Fisher, M. Alshahrani, N. Alzahrani, S. Valle, W. Liauw, D. Morris (Australia)

C85

A multi-faceted experimental approach uncovers a novel therapeutic strategy for colorectal peritoneal carcinomatosis.

C.A.J. Ong, J. Hendrikson, W.H. Ng, X. Qiu, J.W.S. Tan, N.B. Shannon, C.S. Chia, G.H.C. Tan, K.C. Soo, O.L. Kon, M.C.C. Teo (Singapore)

C86

Outcome of cytoreductive surgery + HIPEC in low volume colorectal cancer with peritoneal metastasisis.

M. Rahman, N. Alzahrani, S. Valle, W. Liauw, D. Morris (Australia)

C87

Long-term survival after cytoreductive surgery and hyperthermic chemotherapy is possible for patients with colorectal cancer peritoneal metastasis.

S. Hurton, Y. Xu, J. Rivard, M.L. Quan, L. Mack, W. Temple, A. Bouchard-Fortier (Canada)

C88

Mentored set-up of a peritoneal malignancy centre: early outcomes in 50 patients.

N. Ansari, K.G.M. Brown, C.E. Koh, K. Mcbride, D. Steffens, J.M. Young, C.J. Young, M.J. Solomon (Australia), B.J. Moran (UK)

C89

Quality of life following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: short term outcomes from a prospective cohort study.

N. Ansari, C.E. Koh, K.G.M. Brown, D. Steffens, J.M. Young, C.J. Young, M.J. Solomon (Australia), B.J. Moran (UK)

C90

Pre-operative neutrophil-lymphocyte ratio predicts for post-operative infective complications in patients undergoing crs and HIPEC.

W. Wang, C.J.J. Seo, G.H.C. Tan, C.S. Chia, J.C.A. Ong, K.C. Soo, M.C.C. Teo (Singapore)

C91

Evaluation of morbidity, mortality and health related quality of life for concentration-based and bsa-based HIPEC in colorectal peritoneal surface malignancy treatment.

L. Lemoine, E. Thijssen, R. Carleer (Belgium), P. Sugarbaker (USA), K. Van Der Speeten (Belgium)

C92

Treatment of peritoneal dissemination in stomach cancer patients with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC): first results of the periscope i study.

R.T. Van Der Kaaij, E.C.E. Wassenaar, W.J. Koemans, K. Sikorska, H. Boot, C. Grootscholten, J.H.M. Schellens, M. Los, K.J. Hartemink, A.A.F.A. Veenhof, C.P. Hahn, A.P.I. Houwink, D. Boerma, B. Van Ramshorst, J.W. Van Sandick (Netherlands)

C93

Survival and cost-effectiveness of hipec in colorectal peritoneal carcinomatosis treated at ipo porto.

A. Sousa, M. Peyroteo, J.C. Pereira, P. Redondo, F. Senra, D. Brito, F. Sousa, M. Fernandes, J.F. Videira, J. Abreu De Sousa (Portugal)

C94

Wide variation in intraperitoneal chemotherapy concentrations during hipec in patients treated for colorectal peritoneal metastases.

F.M.K. Elekonawo, W.J. Van Eden, W.Y. Van Der Plas, R.S.G. Ewalds, A.J.A. Bremers, P.H.J. Hemmer, N.F.M. Kok, S. Kruijff, A.G.J. Aalbers, P.R. De Reuver (Netherlands)

C95

Postoperative complications after hipec with oxaliplatin and docetaxel in gastric cancer patients with peritoneal dissemination.

W.J. Koemans, R.T. Van Der Kaaij, E.C.E. Wassenaar, K. Sikorska, H. Boot, C. Grootscholten, M. Los, K.J. Hartemink, A.A.F.A. Veenhof, C.P. Hahn, A.P.I. Houwink, D. Boerma, B. Ramshorst, J.W. Sandick (Netherlands)

C96

A nomogram for predicting peritoneal metastases in stage ii-iii colon cancer patients after radical resection.

G. Cai, W. Dai, S. Mo, W. Xiang, R. Wang, Q. Li, S. Cai, Y. Xu (China)

C97

Nephrotoxic effects of cisplatin combined with mitomycin c in laparoscopic hyperthermic intraperitoneal chemotherapy.

K. Robinson, R. Kapoor, P. Owusu-Agyemang, J. Cata, P. Mansfield, B. Badgwell (USA)

C98

Repeated cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.

A. Nissan, S. Goren, A. Ben-Yaacov, D. Perelson, E. Shmueli, D. Aderkad, G. Schtrechman, T. Kaplon, D. Zippel, A. Al-Kurd (Israel)

C99

Laparoscopic cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with colorectal cancer peritoneal metastasis.

S.C. Chang (China)

C100

First experience in cytoreductive surgery and hipec for metastatic peritoneal disease at ramon y cajal hospital: 25 first patients.

L.D. Juez, P. Muñoz, M. Cuadrado, V. Pachón, J. Cabañas, J. Galindo (Spain)

C101

Comparison of long terms outcomes after surgical management of peritoneal and/or liver metastasis from neuroendocrine tumors.

L. Benhaim, M. Faron, M. Gelli, I. Sourrouille, J.Y. Scoazec, A. Berdeloux, J. Hadoux, S. Hescot, C. Patriarche, E. Baudin, D. Goere (France)

C102

HIPEC: closed technique with co2 recirculatoin in the multimodal treatment of peritoneal carcinomatosis.

E. Ovejero, A. Gutiérrez, R. Gómez, A. López, I. Lasa, R. Marcos, R. Medina, L. Jiménez, R. Alvarado (Spain)

C103

Survival after surgical exploration for intended HIPEC patients with extended disease.

J.A. Funder, L. Hommelgaard, M.M. Sørensen, L.H. Iversen, V.J. Verwaal (Denmark)

C104

Safety of bidirectional chemotherapy with dianeal as carrier fluid in an experienced centre.

J.F. Funder, L.H. Iversen, M.M. Sørensen, V.J. Verwaal (Denmark)

C105

Interobserver and interlaboratory variability in the reporting of pt4a in colon cancer.

C. Klaver, N. Bulkmans, P. Drillenburg, H. Grabsch, N. Van Grieken, A. Karrenbeld, L. Koens, I. Van Lijnschoten, J. Meijer, I. Nagtegaal, X. Sagaert, K. Seldenrijk, M. Van Velthuysen, L. Overbeek, P. Tanis, P. Snaebjornsson

C106

Abdominal wall metastasis in patients with peritoneal metastasis of colorectal cancer treated with CRS+HIPEC.

E. Wassenaar, F. Hoogwater, R. Wiezer, D. Boerma, B. Van Ramshorst (Netherlands)

C107

Systematic review of protocols used for hyperthermic intraperitoneal chemotherapy (HIPEC) after cytoreductive surgery of peritoneal metastasis from colorectal cancer.

C. Yurttas, G. Hoffmann, S.P. Haen, A. Königsrainer, S. Beckert, M.W. Löffler (Germany)

C108

Peritoneal metastasis (PM) from colonic origin. 423 patients treated by CRS+ HIPEC. catalonian peritoneal carcinomatosis program.

I. Ramos Bernadó, P. Barrios Sanchez, O. Crusellas Maña, M. Martín Baranera, D. Sabia (Spain)

C109

Peritoneal metastasis (PM) from gastric origin. 45 consecutive patients treated with radical cytorreduction and hyperthermic intraperitoneal chemotherapy (CRS + HIPEC). results from the catalonian peritoneal carcinomatosis program.

D. Sabia, I. Ramos Bernadó, O. Crusellas Maña, M. Martín Baranera, P. Barrios Sanchez (Spain)

C110

Iterative CRS + HIPEC procedures (IHIPEC). experience and results of the peritoneal catalonia carcinomatosis program.

I. Ramos Bernadó, D. Sabia, O. Crusellas Maña, M. Martín Baranera, P. Barrios Sanchez (Spain)

C111

1000 CRS + HIPEC procedures. Efficiency and safety results.

I. Ramos Bernadó, D. Sabia, O. Crusellas Maña, M. Martín Baranera, P. Barrios Sanchez (Spain)

C112

And HIPEC for gastric coutcome in patients treated with cytoreductive surgeryancer and peritoneal carcinomatosis.

F.B. Braeuer, H.W. Wundsam, F.B. Fischer, G.P. Pressl, R.F. Fuegger, K.R. Rohregger (Austria)

C113

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a single-center experience in Portugal.

C. Fernandes, J. Simões, F. Sousa, V. Devezas, S. Meireles, C. Sarmento, M. Aral, T. Machado, R. Melo, J. Costa-Maia (Portugal)

C114

Rectal resection does not increase the major morbidity in patients undergoing crs and hipec for colorectal pm- a report from the indian hipec registry.

S. Mehta, P. Kammer, S. Zaveri, D. Damodaran, M. Ray, S. Sinukumar, R. Seshadri, A. Bhatt (India)

C115

CRS and HIPEC in the eldery.

A. Nissan, A. Bilik, J. Dux, A. Ben-Yaacov, D. Perlson, D. Zippel, V. Ivanov, S. Yehuda, G. Schtrechman, T. Kaplun, A. Al-Kurd (Israel)

C116

Neoadjuvant bidirectional chemotherapy combining intraperitoneal docetaxel with intravenous 5-fluorouracil and oxaliplatin for patients with non-resectable peritoneal carcinomatosis from gastric cancer: the first pilot study in western countries.

R. Lo Dico, J.M. Gornet, N. Guglielmo, F. Bart, A. Zaanan, J. Taieb, M. Pocard (France)

C117

CRS with HIPEC for peritoneal carcinomatosis of pancreatic adenocarcinoma. what do we expect? results of a multicenter international study.

L. Schwarz (France), E.A. Levine (USA), D.L. Morris (Australia), J. Spiliotis (Greece), O. Glehen (France), D.L. Bartlett (USA), M. Pocard (France), R. Kianmanesh (France), Y. Yonemura (Japon), P. Cashin (Suède), A.A.K. Tentes (Greece), L. Villeneuve (France)

C118

Cytoreductive surgery and HIPEC – the polish experience.

T. Jastrzebski, W. Polkowski, W. Zegarski, M. Bebenek, P. Richter, T. Olesinski, T. Polec, B. Kapturkiewicz, J. Mielko (Poland)

C119

Failure to return to intended oncological treatment (RIOT) after HIPEC impairs prognosis in gastric peritoneal carcinomatosis- analysis of the big-renape group.

P.E. Bonnot, G. Passot, E. Decullier, F. Quenet, D. Goere, K. Abboud, M. Pocard, P. Meeus, J.M. Bereder, S. Msika, C. Arvieux, D. Pezet, P. Rat, R. Wernert, T. Courvoisier, N. Pirro, O. Glehen (France), F.J. Lacueva (Spain)

C120

The role of peritonectomy in CRS plus HIPEC.

M.C. Hsieh, C.Y. Lu, H.H. Yu, W.W. Chang, P.K. Hsiao, Y.H. Wang (Taiwan, Republic of China)

C121

Impact on the hemorrhagic complications of HIPEC with oxaliplatin of the application of a protocol of high dosage of intravenous albumin.

D. Cortes-Guiral, I. Lopez-Rojo, J. Barambio, A. Sanchez, I. Prieto, I. Guijo-Castellano, A. Badia, S. Jimenez De Los Galanes, H. Guadalajara, D. Garcia-Olmo (Spain)

C122

Second-look surgery and HIPEC for patients at high risk of peritoneal carcinomatosis of colo-rectal origin.

I. Lopez-Rojo, D. Cortes-Guiral, J. Barambio-Buendía, A. Leon-Carbonero, I. Martin-Valades, I. Guijo-Castellano, A. Badia, I. Prieto, S. Jimenes De Los Galanes, H. Guadalaraja, D. Garcia-Olmo (Spain)

C123

Impact of ovarian metastases on survival in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal malignancy of appendiceal and colorectal cancer origin.

A. Mehta, M. Bignell, S. Alves, K. Chandrakumaran, S. Dayal, F. Mohamed, T. Cecil, B. Moran (UK)

C124

Two-stage cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei with high peritoneal carcinomatosis index.

L. Sidéris, B. Trilling, R. Hamad, P. Dubé, P. Richebe, A. Mitchell (Canada)

C125

Sclerosing encapsulating peritonitis secondary to cytoreductive surgery and HIPEC.

G. Liberale (Belgium), M. Pocard (France), S. Mehta (India), W. Ceelen (Belgium), F. Arias (Colombia), O. Glehen (France), P. Sugarbaker (USA)

C126

Selection and clinical characteristics of exceptional/poor responders in peritoneal dissemination from appendiceal origin treated with CRS/HIPEC.

C. Munoz-Zuluaga, M.C. King, A. Sardi, P. Ledakis, M. Sittig, C. Nieroda, V. Gushchin (USA)

C127

Molecular features of patients affected by colon cancer peritoneal carcinomatosis treated with CRS and HIPEC.

L. Graziosi, E. Marino, C. Vannoni, A. Donini (Italy)

C128

Survival analysis of patients treated with crs and HIPEC in ontario.

A. Mccart, E. Taylor, M. Nardin, D. Bischof, A. Govindarajan (Canada)

C129

Long-term outcomes with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in peritoneal carcinomatosis: 10-year experience from a joint commission international certified center in a developing country.

F. Arias, E. Londoño-Schimmer, J. Otero, C. Cétares, G. Herrera-Almario, M. Mora, M. Rodriguez, S. Rodriguez, D. Montaño, J.D. Guerra, A.F. Cardona (Colombia)

C130

Thromboembolic events related to cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).

F. Arias, E. Londoño-Schimmer, J. Otero, C. Cétares, G. Herrera-Almario, M. Mora, M. Rodriguez, S. Rodriguez, D. Montaño, J.D. Guerra, A.F. Cardona (Colombia)

C131

A synergy of stroma and epithelium contributes to tumour biology and overall survival.

N.B. Shannon, X.T. Qui, D. Ng, C.A.J. Ong, M.C.C. Teo (Singapore)

C132

The cumulative incidence of metachronous peritoneal metastases of UICC II/III PT4 colorectal cancer.

P. Schredl, A. Dinnewitzer, D. Neureiter, S. Ciftci, J. Holzinger, J. Presl, K. Emmanuel, T. Jäger (Austria)

C133

Laparoscopic gastrectomy on stage 4 gastric cancer.

S.H. Min, Y.S. Cho, Y.S. Park, S.H. Ahn, D.J. Park, H.H. Kim (Korea)

C134

Peritoneal surface calculator (pesuca): a tool to quantify the resected peritoneal surface area after cytoreductive surgery.

T. Jäger, A. Dinnewitzer, P. Schredl, D. Neureiter, M. Fallaha, S. Ciftci, T. Kiesslich, K. Emmanuel (Austria)

C135

Ras mutation confers prognostic significance in patients undergoing CRS-HIPEC for colorectal cancer.

C. Clarke, Z. Morgan, M. Hembrook, S. Tsai, K. Christians, H. Mogal, T.C. Gamblin (USA)

C136

The risk of peritoneal metastases in patients with PT4A versus PT4B colon cancer.

V.P. Bastiaenen, C.E.L. Klaver, K.A.T.G.M. Wasmann, I.D. Nagtegaal, B. Van Ramshorst, A.M. Wolthuis, J.D.W. Van Der Bilt, H.C. Van Santvoort, J.H.W. De Wilt, A.D. D' Hoore, P.J. Tanis (Netherlands)

C137

Current morbidity and mortality outcomes of cytoreductive surgery with heated intraperitoneal chemotherapy.

M. Peyroteo, A. Cruz, A.R. Monteiro, P. Carvalho Martins, R. Canotilho, A. Sousa, F. Senra, D. Brito, F. Sousa, M. Fernandes, F. Faria, A. De Sousa (Portugal)

C138

Continuous evolution in complex surgical procedures: lessons learned from a peritoneal surface malignancy center.

A. Ben-Yaacov, Y. Dux, A. Bilik, M. Adilah, G. Shtrechman, D. Aderka, E. Shacham-Shmueli, A. Hubert, A. Beny, D. Hazzan, D. Zippel, A. Nissan (Israel)

C139

Retrospective analysis of adjuvant systemic chemotherapy in patients with peritoneal metastasis of colorectal cancer treated with CRS+HIPEC.

E.C.E. Wassenaar, K.P. Rovers, R.J. Lurvink, F.J.H. Hoogwater, nS.W. Nienhuijs, M.J. Wiezer, I.J.H.T. De Hingh, D. Boerma (Netherlands)

C140

Primary tumor location predicts colorectal carcinomatosis burden in patients undergoing cytoreductive surgery despite KRAS or LVI status.

K. Lafaro, O. Eng, A. Blakely, M. Raoof, B. Lee (USA)

C141

Clinical outcomes of patients with extensive peritoneal carcinomatosis of colorectal or appendiceal origin undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

N.L. De Boer, K. Rovers, E.V. Madsen, A.R. Brandt, C. Verhoef, I.H. De Hingh, J.W. Burger (Netherlands)

C142

Blood transfusion is associated with poor survival in patient treated with CRS and HIPEC for peritoneal metastasis.

G. Mariano, E. Gayat, R. Schiavone, S. Dagois, M. Pocard, C. Eveno (France)

C143

Surgery characteristics and treatment of hemorrhagic complication after cytoreductive surgery hyperthermic intra peritoneal chemotherapy: a retrospective cohort study of 67 patients.

H. Courcier, G. Mariano, E. Gayat, M. Ledorze, M. Pocard, C. Eveno (France)

C144

The role of perioperative chemotherapy for peritoneal metastases of colorectal cancer origin treated with curative intent.

G. Liberale, D. Repullo, S. Barbois, D. Leonard, A. Bohlok, E. Thys Van Den Audenaeren, A. Hendlisz, M. Van Den Eynde, A. Kartheuser (Belgium)

C145

Surgery and empathy: two sides of an optimized treatment of patients with peritoneal diseases.

L. Robieux, F. Zenasni, C. Flahault, M. Pocard, C. Eveno (France)

C146

Cytoreduction and hipec in the treatment of colorectal peritoneal metastasis. morbidity, mortality and survival.

V. Concepcion Martin, C. Diaz, R. Gianchandani, J.M. Sanchez, C. Chocarro, E. Moneva, M. Barrera (Spain)

C147

Selection of the optimal chemotherapy regimen for hipec in gastric cancer with peritoneal metastasis- french multicenter analysis for the big-renape group.

K. Polom (Poland), P.E. Bonnot, E. Decullier, L. Villeneuve, M. Pocard, F. Quenet, J.M. Bereder, P. Meeus, K. Abboud, S. Msika, P. Rat, C. Arvieux, T. Courvoisier, A. Lefevre, D. Pezet, N. Pirro, R. Wernert, R. Kianmanesh, D. Goere, O. Glehen (France)

C148

Safety and efficacy of perioperative systemic therapy with cytoreductive surgery and hipec versus upfront surgery with hipec alone for isolated resectable colorectal peritoneal metastases: update of a multicentre, open-label, parallel-group, phase II-III, randomised superiority study (CAIRO6).

K. Rovers, J. Burger, R. Wiezer, A. Aalbers, J. Tuynman, S. Radema, E. Van Duyn, H. Van Grevenstein, P. Hemmer, P. Tanis, C. Punt, I. De Hingh (Netherlands)

C149

The presence of braf V600E mutation doesn't contraindicate a cytoreductive surgery and hipec in patients with peritoneal metastases from colorectal cancer.

R. Lo Dico, A. Dohan, R. Kaci, K. Pautrat, B. Malgras, T. Andre, M. Pocard (France)

C150

Effects of neoadjuvant intraperitoneal/systemic chemotherapy (NIPS) on peritoneal metastasis and lymph node metastasis of gastric cancer.

Y. Yonemura (Japan)

C151

Patterns of abdominal surface thermography imaging during closed HIPEC.

P. Schredl, A. Dinnewitzer, D. Neureiter, S. Ciftci, M. Fallaha, J. Holzinger, K. Emmanuel, T. Jäger (UK)

C152

Epidemiology and survival impact of synchronous peritoneal metastases of epithelial malignancies: a nationwide population-based observational study.

K. Rovers, P. Vissers, L. Vaartjes, T. Van Oudheusden, W. Van Driel, J. De Wilt, J. Burger, P. Tanis, N. Kok, V. Lemmens, I. De Hingh (Netherlands)

C153

Role of perioperative chemotherapy (pc) with cytoreductive surgery (CRS) and hyperthermic intraperitoneal CHEMOTHERAPY (HIPEC) for colorectal cancer (CRC) carcinomatosis.

N. Hanna, A. Hanna, C. Boutros, D. Hanna (USA)

C154

Underutilization of aggressive treatment approaches in patients with colorectal and gastric peritoneal carcinomatosis-analysis of the national cancer database.

G. Salti, S. Naffouje (USA)

C155

Prognostic variables in colorectal peritoneal carcinomatosis: an evaluation of a single asian centre's experience.

W.L. Loh, H.C.G. Tan, S.C. Chia, C.A.J. Ong, C.C.M. Teo (Singapore)

PERITONEAL MALIGNANCIES AND HIPEC AND NURSES

J1

Health & well being support & assessment of satisfaction for patients with peritoneal tumours.

R. Halstead (UK)

J2

Making sense of cost- effectiveness of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with colorectal peritoneal carcinomatosis.

Z.J. Lee, C.C. Chia, G. Tan, J. Ong, K.C. Soo, M. Teo (Singapore)

J3

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for patients with peritoneal surface malignancy: the initial experience of a reference center in peritoneal diseases in southern brazil.

R. Seitenfus, L.B. Gravina, A.P. Santos, A.D. Pizzol Junior, R. Boldo, A. Basso Junior, C.H. Cereser Junior, G.A. Laporte, M.M. Coimbra, D.F.M. Riveiro (Brazil)

J4

Stapled versus hand-sewn intestinal anastomosis in patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC).

D. Cox, K. Robinson, S. Rafeeq, O. Shayeb, K. Hess, P. Mansfield, R. Royal, K. Fournier (USA)

J5

Short-term outcomes following cytoreductive surgery and heated intra-peritoneal chemotherapy at waikato.

S. Lolohea, M.J. Karalus, J. Ly, L. Wu, R. Van Dalen (New Zealand)

J6

Impact of gargantuan peritoneal disease on surgical outcomes in australia's highest volume centre.

J. Mcafee, V. Saunders, H. Kennedy, A. Sarkar, N. Alzahrani, O. Fisher, D. Morris, W. Liauw (Australia)

PERITONEAL MESOTHELIOMA AND PSEUDOMYXOMA PERITONEI

D01

Adjuvant dendritic cell based immunotherapy (DCBI) after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma: rationale and design of the mesopec study.

N.L. De Boer, J. Van Kooten, A. Brandt, C. Verhoef, J.W. Burger, J.G. Aerts, E.V. Madsen (Netherlands)

D02

Recommendations for radiological follow-up based on 775 patients treated by cytoreductive surgery and HIPEC for appendiceal pseudomyxoma peritonei.

K. Govaerts, K. Chandrakumaran, N. Carr, C. Thomas, D. Sanjeev, M. Faheez, T. Andrew, M. Brendan (UK)

D03

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei of appendicular and extra-appendicular origin.

J.B. Delhorme, F. Severac, G. Averous, O. Glehen, G. Passot, N. Bakrin, F. Marchal, M. Pocard, R. Lo Dico, C. Eveno, S. Carrere, O. Sgarbura, F. Quenet, G. Ferron, D. Goéré, C. Brigand (France)

D04

Impact of previous major gynecological surgical procedures on short term and oncological outcomes in patients treated with CRS and HIPEC.

M. Guaglio, D. Baratti, S. Kusamura, E. Nizri, L. Battaglia, M. Deraco (Italy)

D05

Abdominal mesothelioma in a swedish national population-based study.

P. Cashin, G. Jansson Palmer, D. Asplund, W. Graf, I. Syk (Sweden)

D06

Interim analysis of a prospective, randomised phase 2 study in patients undergoing cytoreductive surgery for pseudomyxoma peritonei: haemostatic efficacy and safety of fibrinogen concentrate and cryoprecipitate.

A. Roy, N. Sargant, S. Rangarajan, S. Alves, J. Bell, S. Stanford, C. Solomon, I. Kruzhkova, S. Knaub, F. Mohamed (Switzeland)

D07

Treatment options of malignant peritoneal mesothelioma in finland during years 2000 – 2012.

S.A.S. Salo, I. Ilonen, S. Laaksonen, M. Myllärniemi, J.A. Salo, T. Rantanen (Finland)

D08

A review on debulking surgery for unresectable pseudomyxoma peritonei – to do or not to do?

C.J. Seo, W. Wang, H.C.G. Tan, S.C. Chia, C.C.M. Teo (Singapore)

D09

Mode of presentation in 1070 patients with perforated epithelial appendiceal tumours treated in a peritoneal malignancy unit.

U. Shariff, H. Seretis, K. Chandrakumaran, S. Dayal, F. Mohamed, T. Cecil, B. Moran (UK)

D10

CA 19-9 to peritoneal carcinomatosis index (PCI) ratio is prognostic in patients with epithelial appendiceal mucinous neoplasms and peritoneal dissemination undergoing cytoreduction surgery and intraperitoneal chemotherapy.

R. Shamavonian, M.A. Kozman, O.M. Fisher, B.J. Rebolledo, S.J. Valle, N. Alzahrani, W. Liauw, D.L. Morris (Australia)

D11

Repeat cytoreductive surgery-hyperthermic intraperitoneal chemoperfusion is feasible and offers survival benfit in select patients with peritoneal metastases.

H. Choudry, Y. Shuai, H. Jones, J. Pingpank, S. Ahrendt, M. Holtzman, H. Zeh, D. Bartlett (USA)

D12

Diffuse malignant peritoneal mesothelioma - survival with complete cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC).

E. Wagler (Germany)

D13

Pseudomyxoma peritonei from ovarian origin. report on 18 cases from french collaborative network renape.

W. Gertych, E. Decullier, F. Quenet, D. Goere, G. Ferron, G. Lorimier, F. Marchal, L. Villeneuve, O. Glehen (France)

D14

Early outcomes from a national peritoneal mesothelioma multi disciplinary team (NPMMDT) meeting in the united kingdom (UK) and ireland.

A. Brandl, K. Govaerts, D. Yershov, A. Plastiras, S. Nunn, S. Dayal, F. Mohamed, B. Moran, T. Cecil (UK)

D15

Factors affecting early recurrence of low-grade appendiceal mucinous neoplasms following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC).

M.S. Alshahrani, O.M. Fisher, S.J. Valle, N.A. Alzahrani, W. Liauw, D.L. Morris (Australia)

D16

Addressing psychological distress in a surgical setting.

N. Vanderpuye, E. Arbuthnot, J. Crow, B. Moran, T. Cecil (UK)

D17

Does the level of carcinoembryonic antigen correlate to the peritoneal carcinomatosis index and predict postoperative complications in patients with pseudomyxoma peritonei?

G. Palmer, L. Hartwig (Sweden)

D18

Well differentiated papillary peritoneal mesothelioma- outcome analysis of to the psogi international registry.

M. Deraco, E. Nizri, O. Glehen, D. Baratti, J.J. Tuech, J.M. Bereder, V. Kepenekian, S. Kusamura, D. Goere (France)

D19

Redo cytoreductive surgery (CRS) with heated intraperitoneal chemotherapy (HIPEC) – a single uk specialist centre experience.

S. Kumari, C. Selvasekar, O. Aziz, M. Wilson, A. Renehan, S. O'dwyer (UK)

D20

Systemic chemotherapy in appendiceal adenocarcinomas with peritoneal metastases. Is it worth it?

F.J. Morera Ocon, F. López Mozos, R. Martí Obiol, J. Ortega Serrano, B. Camps Vilata (Spain)

D21

Survivorship and quality of life in patients who have undergone cytoreductive surgery and HIPEC: a pilot study.

D.A. Bischof, E.L. Taylor, J.A. Mccart, A. Govindarajan (Canada)

D22

Role of oral metronomic chemotherapy (OMCT) after CRS+/-HIPEC in poor prognosis peritoneal mesothelioma.

P. Kammar, A. Girkar, J. Anam, V. Maniar, A. Gore, A. Bhatt, S. Mehta (India)

D23

Laparoscopic versus open cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for perforated low grade appendiceal mucinous neoplasms.

H. Abudeeb, L. Malcomson, B. Chakrabarty, M. Wilson, A. Renehan, P. Fulford, S. O'dwyer, C. Selvasekar, O. Aziz (UK)

D24

Comparison of two preoperative prognostic tools to select patients for cytoreductive surgery and HIPEC in diffuse malignant peritoneal mesothelioma.

S. Kusamura, D. Baratti (Italy), K. Chandrakumaran, B.J. Moran, N.J. Carr (UK), M. Guaglio, M. Deraco (Italy)

D25

Management of malignant peritoneal mesothelioma in the era of bidirectional chemotherapy: mid-term results in a single-institution experience.

M. Gelli, I. Sourouille, F. Le Roy, V. Boige, L. Benhaim, D. Malka, C. Smolenschi, M. Ducreux, M. Faron, A. Laurenzi, P. Dartigues, C. Honoré, A. Hollebecque, D. Goéré (France)

D26

Staged CRS/HIPEC: an approach for difficult cases of indolent peritoneal surface malignancy.

R. Royal, K. Robinson, D. Cox, A. Arrington, K. Beaty, O. Shayeb, S. Rafeeq, A. Hayes-Jordan, P. Mansfield, K. Fournier (USA)

D27

Neutropenia following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy with mitomycin c is associated with longer length of stay and increased postoperative complications.

S. Dineen, P. Shah, S. Dessureault (USA)

D28

CRS+HIPEC for peritoneal carcinomatosis of appendiceal origin with high tumor load.

T. Kitai, K. Yamanaka (Japan)

D29

Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) for pseudomyxoma peritonti (PMP) - 15 years' experience from wanfang hospital, Taiwan.

C.Y. Lu, M.C. Hsieh, H.H. Yu (Taiwan, Republic of China)

D30

Complete pathologic response after two-stage cytoreductive surgery with hipec for pseudomyxoma peritonei.

O. Sgarbura (France), A. Petruzziello (Brazil), R. Figueroa (Argentina), L. Khellaf, M.H. Pissas, S. Carrere, S. Nougaret, F. Bibeau, F. Quénet (France)

D31

CRS and HIPEC for huge pseudomyxomas : experience of a tertiary cancer centre in india.

R. Ayloor Seshadri, R. Reddy Yarram, G. Das, H.R. Ellusamy (India)

D32

Peritoneal involvement is more common than nodal involvement in patients with high-grade appendix tumors undergoing prophylactic cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

A. Mehta, R. Mittal, K. Chandrakumaran, N. Carr, S. Dayal, F. Mohamed, B. Moran, T. Cecil (UK)

D33

Total gastrectomy as parts of cytoreductive surgery for patients with pseudomyxoma peritonei.

S.Y. Park, M.C. Lim, B.W. Eom, H.M. Yoon, S.S. Han, S.H. Kim, C.W. Yoo (Korea)

D34

One center detailed analysis of CRS + HIPEC interventions performed in patients suffered from diffuse malignant peritoneal mesothelioma (DMPM).

M.S.N. Nowacki, W. Zegarski (Poland)

D35

Peritoneal mesothelioma, in mexico ?

A.Vázquez-García, J. Vázquez Limón (Mexico)

D36

CRS and HIPEC in mucinous cystoadenocarcinoma of the uracus.

S. Sanchez-Garcia, E. Garcia-Santos, P. Villarejo-Campos, D. Padilla-Valverde, J. Martin-Fernandez (Sapin)

PERITONEAL METASTASES FROM OVARIAN CARCINOMA

E01

Prognostic factors for early recurrences following cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for primary ovarian peritoneal metastases.

N. Chandran, G. Tan, C. Chia, M. Teo (Singapore)

E02

A protocolised approach to preventing nephrotoxicity in HIPEC with cisplatin.

E. Sin, C. Chia, M. Teo (Singapor)

E03

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of epithelial ovarian cancer in mexico. report on the first ten years of experience.

J.M. Medina-Castro, H.N. Lopez-Basave, H. Medina-Franco, G. Flores-Ayala, A.B. Gonzalez-Valdez, F. Rivera-Buendia, J. Esquivel (Mexico)

E04

Evaluation of the peritoneal surface disease severity score (PSDSS) in ovarian cancer patients undergoing cytoreductive surgery and HIPEC: two pathogenetic types based study.

R. Yarema, T. Fetsych, N. Volodko, M. ?Horchak, O. Petronchak, R. Huley, Y. Mylyan, M. Fetsych (Ukraine), O. Glehen (France)

E05

A comparative analysis of clinical outcomes after interval and secondary cytoreductive surgery (CRS) and hyperthermicintraperitoneal chemotherapy (HIPEC) In locally advanced ovarian cancers.

M.D. Ray, J.S. Saikia, N.K. Kumar, S.V.S. Deo (India)

E06

Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC) for managing primary high-grade tubo-ovarian serous carcinoma in patients with diffuse peritoneal metastases: a series of 81 cases from a tertiary center experienced in treating peritoneal surface malignancies.

T. Cornali, D. Biacchi, A. Impagniatiello, B.M. Sollazzo, R. Marcellinaro, L. Carbonari, A. Fassari, P. Sammartino (Italy)

E07

Updated preliminary results of a phase ii randomized clinical trial - CRS/HIPEC as initial treatment of ovarian, fallopian tube, and primary peritoneal cancer.

A. Sardi, T. Diaz-Montes, H. Ryu, J. Ducie, F. El-Sharkawy, M. Sittig, V. Gushchin (USA)

E08

Early experience in the use of CRS and HIPEC in patients with ovarian cancer.

I. Kyriazanos, V. Kalles, D. Papageorgiou, E. Fradelos, I. Papapanagiotou, N. Stamos, M. Zoulamoglou, K. Pagonis, N. Ivros (Greece)

E09

Our initial experience of CRS & HIPEC in peritoneal metastasis from carcinoma ovary and review of postoperative outcomes.

N.S. Seeralan, S. Sundaram, P. Prakasam (India)

E10

The role of small bowel PCI (SB-PCI) in patients with peritoneal metastasis from ovarian cancer: a new prognostic factor?

J. Spiliotis, A. Terras, N. Kopanakis, A. Prodromidou, M. Ferfelis, E. Efstathiou (Greece)

E11

Cisplatin plus doxorubicin or paclitaxel in hyperthermic intraperitoneal chemotherapy (HIPEC) for stage IIIC or IV epithelial ovarian cancer.

I. Manzanedo, F. Pereira, E. Pérez-Viejo, Á. Serrano, B. Martínez-Torres, C. Rihuete (Spain)

E12

Relapsed ovarian cancer : the r-r dilemma (residual or recurrent disease).

N. Kopanakis, J. Spiliotis, A. Rogdakis, C. Iavazzo, N. Spiliotis, M. Ferfelis, A. Raptis, N. Zampitis, E. Efstathiou (Greece)

E13

The role of repeated cytoreductive surgery plus HIPEC in peritoneal carcinomatosis recurrence: a retrospective analysis.

J. Spiliotis, A. Prodromidou, N. Kopanakis, M. Ferfelios, A. Raptis, A. Terra, E. Efstathiou, M. Alexandratou (Greece)

E14

Cytoreductive surgery with adjuvant systemic therapy followed by interval consolidation hyperthermic intraperitoneal chemotherapy : a novel paradigm for ovarian cancer.

J. Veerapong, J. Baumgartner, B. Duggan, A. Bahador, R. Low, A. Lowy, R. Barone (USA)

E15

Hyperthermic intraperitoneal chemotherapy in stage IIIC and iv clinical stage ovarian carcinoma during interval laparotomy. phase II study. interim analysis of morbility and perioperative mortality.

R. Salcedo-Hernández, L. Cetina, D. Cantú-De-León, V. Córdoba, R. Tiznado, D. Isla-Ortiz, D. Gallardo-Rincón, Á. Herrera-Gómez (Mexico)

E16

Morbidity after cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC) used in treatment of ovarian, tubal and primary peritoneal cancer.

M.S. Mikkelsen, T. Christiansen, L.K. Petersen, J. Blaakaer, L.H. Iversen (Denmark)

E17

Long term results of cytoreductive surgery and HIPEC in high grade "ovarian cancer". a single-center retrospective study.

F. Laminger, C. Koppitsch, S. Roka, F. Kober (Austria)

E18

Splenectomy during cytoreductive surgery for ovarian cancer.

J. Spiliotis, N. Kopanakis, P. Koustas, A. Ntinas, T. Metaxas, D. Farmakis, E. Efstathiou (Greece)

E19

CRS with HIPEC in stage IIIC epithelial ovarian cancer with comparison of oncological outcome only with CRS + intravenous chemotherapy & crs plus normothermic port based intra-peritoneal chemotherapy.

S.P. Somashekhar, C. Rohit Kumar, S. Zaveri, K.R. Ashwin, Y. Ramya, A. Rauthan, V. Ahuja (India)

E20

Prediction model for suboptimal cytoreduction during interval cytoreductive surgery in patients with peritoneal carcinomatosis from ovarian cancer treated by neoadjuvant chemotherapy.

J.H. Son, S.J. Chang, T.W. Kong, J. Paek, H.S. Ryu (Korea)

E21

Extent of peritoneal disease in lower abdomen and it's relation to nodal disease in stage 3c epithelial ovarian cancer.

S. Mehta, P. Kammar, S. Waghoo, A. Girkar, J. Anam, A. Bhatt (India)

E22

Surgical management of malignant bowel obstruction in epithelial ovarian cancer recurrent peritoneal carcinomatosis: a preoperative assessment proposal.

A. Di Giorgio, C. Lodoli, S. Rotol, C. Abatini, M. Cintoni, G. Scambia, V. Gallotta, G. Di Flumeri, F. Pacelli (Italy)

E23

Outcomes of stage III and iv ovarian cancers after treatment with neo-adjuvant chemotherapy followed by cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.

T. Diaz-Montes, C. Munoz-Zuluaga, M. Sittig, V. Gushchin, C. Nieroda, A. Sardi (USA)

E24

Validation of a peritoneal surface disease severity score in stage IIIC-IV ovarian cancer treated with cytoreduction and hyperthermic intraperitoneal chemotherapy.

Á.J. Gomez Ruiz, A. González Gil, E. Gil Gomez, J. Gil Gómez, P. Cascales Campos (Spain)

E25

Can the negative prognostic impact of a poor/ moderate response to neoadjuvant chemotherapy be offset by a complete interval cytoreductive surgery in patients with advanced epithelial ovarian, fallopian tube and primary peritoneal cancer ? - a retrospective study by indepso.

A. Bhatt, S. Sinukumar, F. Rajan, D. Damodaran, P. Kammer, S. Zaveri, S. Mishra, S. Mehta (India)

E26

A comparative analysis of clinical outcomes of patients with advanced serous epithelial ovarian, fallopian tube and primary peritoneal cancer following primary versus interval cytoreductive surgery and HIPEC- a study by indepso.

S. Sinukumar, S. Zaveri, F. Rajan, D. Damodaran, P. Kammar, S. Mehta, A. Bhatt (India)

E27

Heated intra-operative versus normothermic post-operative intraperitoneal chemotherapy for recurrent epithelial ovarian carcinoma.

A. Blakely, K. Lafaro, B. Lee, M. Cristea, W.C. Lin, S. Lee, M. Wakabayashi, E. Han, T. Dellinger (USA)

E28

Recurrent ovarian cancer treated with radical cytorreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) : 122 consecutive pacients. Catalonian peritoneal carcinomatosis program.

D. Sabia, O. Crusellas Maña, I. Ramos Bernadó, M. Martín Baranera, P. Barrios Sanchez (Spain)

E29

Cytoreductive surgery and HIPEC as 1st line treatment of ovarian cancer in stages IIIC / IV.

J.M. Sanchez, V. Concepcion, C. Diaz, R. Gianchandani, C. Chocarro, E. Moneva, M. Barrera (Spain)

E30

Evaluation of peritoneal surface disease severity score (PSDSS) adapted in patients with recurrent platinum-sensitive ovarian cancer. A new selection tool.

Á.J. Gómez Ruiz, A. González Gil, E. Gil Gómez, J. Gil Martínez, P. Cascales Campos (Spain)

E31

Respiratory complications after cytoreduction and intraoperative hyperthermic intraperitoneal chemotherapy in ovarian cancer peritoneal carcinomatosis.

A. González Gil, Á.J. Gómez Ruiz, E. Gil Gómez, J. Gil Martínez, P. Cascales Campos (Spain)

E32

Quality of life after a first cytoreduction with or without hipec in ovarian cancer IIIC-IV. Preliminary results of the prospective and randomized clinical trial.

A. González Gil, Á.J. Gómez Ruiz, E. Gil Gómez, J. Gil Martínez, P. Cascales Campos (Spain)

E33

Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy as a new therapeutic strategy for malignant ovarian teratoma with peritoneal dissemination.

H.H. Yu, Y. Yonemura, M.C. Hsieh, C.Y. Lu (Japan)

E34

Outcomes of cytoreductive surgery (CRS) and hipec in patients with peritoneal recurrence from epithelial ovarian cancer- a study by indepso.

P. Kammar, S. Mehta, S. Zaveri, F. Rajan, D. Damodaran, S. Sinukumar, E.H. Raj, A. Bhatt (India)

E35

Palliative HIPEC in platinum-resistant advanced ovarian cancer (first experience).

A. Privalov, A. Vazenin, A. Taratonov, L. Chernova (Russian federation)

E36

Oxaliplatin-based hyperthermic intra-peritoneal chemotherapy for peritoneal recurrence of ovarian cancer: efficient on survival but associate with high haemorrhagic complication.

C. Lecurieux-Lafayette, E. Gayat, H. Courcier, M.J. Caballero, A. Dohan, M. Pocard, C. Eveno (France)

PIPAC

F01

Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is effective in peritoneal carcinomatosis of pancreaticobiliary origin.

P. Horvath, F. Struller, M.A. Reymond, A. Koenigsrainer (Germany)

F02

Implementation of a pipac program in an operating room without laminar airflow : is the procedure safe for the surgeons and their co-workers ?

J.B. Delhorme, A. Klipfel, E. Triki, M.C. Greget, F. D'antonio, S. Rohr, B. Romain, C. Brigand (France)

F04

Pressurized intraperitoneal aerosol chemotherapy (PIPAC) with oxaliplatin, cisplatin and doxorubicin in patients with peritoneal carcinomatosis : analysis of an open-label, single-arm, phase ii clinical trial.

M. Robella, M. Vaira, A. Pisacane, P. Berchialla, M. De Simone (Italy)

F05

Safety and feasibility of pressurized intraperitoneal aerosol chemotherapy (PIPAC). Suggestions from initial experience on non-resectable gastrointestinal or gynecological peritoneal carcinomatosis.

A. Di Giorgio, G. Vizzielli, A. Agnes, S. Rotolo, C. Abatini, A. Strippoli, M.S. D'Antuono, A. Di Mattia, G. Scambia, F. Pacelli (Italy)

F06

Preliminary clinical pipac experience in a french hipec expert center.

A. Ceribelli, A. Maubert, L. Birtwisle, C. Drai, J.L. Bernard, J.M. Bereder (France)

F07

Platinum-induced anaphylactic shocks, post pressurized intraperitoneal aerosol chemotherapy (PIPAC), first literature report.

M. Alyami, M. Siebert, F. Mercier, C. Gallice, L. Villeneuve, F. Berard, O. Glehen, N. Bakrin, V. Kepenekian (France)

F08

Pharmacokinetic study and safety of paclitaxel in pressurized intraperitoneal aerosol chemotherapy (PIPAC) in swine.

H.L. Tan, G.W. Kim, C.E. Chee, A. Shabbir, G. Bonney, C. Charles, R. Li, L.Z. Wang, J.B.Y. So, W.P. Yong (Singapore)

F09

Pharmacokinetic of platin salt during pressurized intraperitoneal aerosol chemotherapy (PIPAC).

C. Arvieux, E. Huart, B. Royer, P.Y. Sage, J. Guevel, J. Abba, B. Busser, X. Fonrose (France)

F10

Feasibility, safety and efficacy of pressurized intraperitoneal aerosol chemotherapy (PIPAC) for peritoneal metastasis : a registry study.

F. Kurtz, F. Struller, H. Philipp, W. Solass, H. Bösmuüller, A. Königsrainer, M.A. Reymond (Germany)

F11

Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for peritoneal metastases in solid organ graft recipients : first experience.

P. Horvath, F. Struller, H. Bösmüller, U. Lauer, S. Nadalin, A. Königsrainer, M.A. Reymond (Germany)

F12

Pressurized intraperitoneal aerosol chemotherapy with low-dose cisplatin and doxorubicin (PIPAC C/D) in patients with gastric cancer and peritoneal metastasis : a phase-ii trial (PIPAC-GA1).

F. Struller, W. Solass, P. Horvath, F.J. Weinreich, D. Strumberg, A. Königsrainer, M.A. Reymond (Germany)

F13

Quality of life of patients with peritoneal metastasis of gastric origin (PMGC) treated with pressurized intraperitoneal aerosol chemotherapy with low-dose cisplatin and doxorubicin (PIPAC C/D) in the salvage situation : results from a phase-II trial.

F. Struller, P. Horvath, F.J. Weinreich, D. Strumberg, A. Königsrainer (Germany)

F14

Electrostatic pressurizd intraperitoneal aerosol chemotherapy for unresectable peritoneal carcinomatosis : experience of 125 procedures.

W. Willaert, L. Van De Sande, P. Pattyn, W. Ceelen (Belgium)

F15

Oxaliplatin use in pressurized intraperitoneal aerosole chemotherapy (PIPAC) is safe and well tolerated : a multicenter study.

O. Sgarbura, M. Hübner, M. Alyami, C. Eveno, J. Gagniere, B. Pache, M. Pocard, O. Glehen, F. Quenet (France)

F16

Fascinating PIPAC – the complex analysis of current ways of pressurized intraperitoneal aerosol chemotherapy development.

M.S.N. Nowacki, W.Z. Zegarski (Poland)

F17

Target tissue effect of hyperthermic intracavitary nanoaerosol therapy (HINAT) : an ex-vivo study.

S. Reck, Y. Sautkin, W. Solass, F.J. Weinreich, K. Schenke-Layland, V. Khosrawipour, M. Reymond (Germany)

F18

Laparoscopic surgery in advanced gastric cancer (T3-4A, N1-3B, M0) combined with high pressure aerosol chemotherapy for peritoneal carcinomatosis (PC) prophylaxis and treatment.

N. Belev (Bulgaria)

F19

Multicenter comprehensive methodological and technical analysis of 832 pressurized intraperitoneal aerosol chemotherapy (PIPAC) interventions performed in 349 patients for peritoneal carcinomatosis treatment : an international survey study.

M.S.N. Nowacki (Poland), M.A. Alyami, L.V. Villeneuve, F. Mercier (France), M. Hubner (Suisse), W. Willaert, W. Ceelen (Belgium), M. Reymond (Germany), D. Pezet, C. Arvieux (France), V. Khomyakov (Russia), L. Lay, S. Gianni (Argentina), W. Zegarski (Poland), N. Bakrin, O. Glehen (France)

F20

First cases of monoportal pressurized intraperitoneal aerossol chemotherapy (PIPAC) in Brazil.

R. Seitenfus, E.D. Barros, A.N. Kalil, L.B. Gravina, A.D. Pizzol Junior, A.P. Santos, R. Boldo (Brazil)

F21

Complications, adverse events and inflamatory response markers in a brazilian case series of patients treated with pressurized intraperitoneal aerossol chemotherapy (PIPAC).

A.D. Pizzol Junior, R. Seitenfus, L.B. Gravina, R. Boldo, A.P. Santos, A. Basso Junior, E.D. Barros, A.N. Kalil, M.M. Coimbra (Brazil)

F22

PIPAC, as an alternative for the treatment of unresectable peritoneal carcinomatosis. Experience of a french center.

J. Guevel, J. Abba, C. Arvieux (France)

F23

Pressurized intraperitoneal aerosol chemotherapy (PIPAC) before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for nonresectable peritoneal metastasis.

M. Alyami, F. Mercier, M. Siebert, P.E. Bonnot, I. Bonnefoy, L. Villeneuve, N. Bakrin, O. Glehen (France)

F24

Renal toxicity after repeated pressurized intraperitoneal aerosol chemotherapy (PIPAC) of unresectable peritoneal metastasis.

V. Larbre, M. Alyami, F. Mercier, N. Vantard, I. Bonnefoy, M.A. Opsomer, L. Villeneuve, N. Bakrin, C. Rioufol, O. Glehen (France)

F25

Does PIPAC C/D potentiate systemic PD-1 immunotherapy for controlling peritoneal metastasis ? report of a long-lasting complete remission in the salvage situation.

F. Struller, M. Dietrich, W. Solass, H. Bösmüller, A. Königsrainer, F. Fend, M. Reymond (Germany)

F26

Assessment of the aerosol distribution pattern of a single-port device for intraperitoneal administration of therapeutic substances.

R.S. Seitenfus, E.D. Dipp Barros, A.K. Kalil Nocchi, G.S. Oliveira Dos Santos, C.Z. Zettler Galleano, C.C. Cereser Junior, G.F. Fedrizzi Zatti, L.L. Marques Siqueira, P.R. Ferreira Walter, R.J. Vargas Alves (Brazil)

F27

Development of an original ex-vivo model allowing real-time pharmacokinetics measurements during drug delivery as pressurized aerosols: the capnocup® model.

I.Sautkin, D. Schnelle, F. Struller, F.J. Weinreich, A. Königsrainer, M. Reymond (Germany)

PRIMARY PERITONEAL MALIGNANCIES

G01

Improved survival with cytoreductive surgery, total parietal peritonectomy and hyperthermic intraperitoneal chemotherapy for serous papillary peritoneal carcinoma-largest single institute experience.

S. Sinukumar, S. Kusamura, D. Baratti, R.A. Salcedo-Hernández, R. Vinayakumar, M. Guaglio, E. Nizri, M. Deraco (Italy)

G02

Peritoneal sarcomatosis in pediatric age treated with cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy : preliminary experience.

A. Sommariva, C. Cona, G. Bisogno, G. Cecchetto (Italy)

G03

Preservation of fertility and ovarian function in young women undergoing HIPEC.

I. Sourrouille, C. Tantardini, P. Dartigues, V. Boige, A. Maulard, D. Elias, C. Poirot, D. Goéré (France)

G04

Predictors of morbidity & mortality after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for patients with ovarian cancer : indian society for peritoneal surface malignancy collaboration study.

A.Kr, S. Sp, S. Zaveri S, R. Kumar, R. Yetahdka, A. Rauthan (India)

RADIOLOGY AND IMAGING

H01

Sarcopenia is not independently associated with worse outcome after cytoreduction and hyperthermic intraperitoneal chemotherapy.

J. Deneve, A. Premji, A. Dyer, Z. Stiles, P. Dicskon, E. Glazer (USA)

H02

Evaluation of magnetic resonance imaging versus computed tomography in the detection of peritoneal disease malignancies.

C. Chia, G. Tan, J. Ong, W.S. Ong, M. Teo (Singapore)

H03

A comprehensive comparison of the five leading scoring systems for peritoneal carcinomatosis from colorectal origin to select CRS/HIPEC candidates with MRI.

M. Engbersen, I. Van 't Sant, J. Velzing, D. Lambregts, H. Van Eden, R. Beets-Tan, A. Aalbers, N. Kok, M. Lahaye (Netherlands)

H04

FDG pet with low dose ct versus contrast enhanced ct as quantification method to assess the extent of peritoneal carcinomatosis previous cytoreductive surgery-HIPEC.

J.J. Segura, A. Repetto, B. Rodriguez, M. Oporto, M. Gimenez, C. De Juan, R. Morales, J. Perez, C. Peña (Spain)

H05

Peritoneal magnetic resonance imaging : preliminary data from a recently implemented protocol.

A.Petruzziello, W.A. Casteleins, V.M. Haida, M. Zapparoli (Brazil)

H06

Infrared thermography monitoring in closed HIPEC to maintain homogenous intraperitoneal temperature distribution.

T. Jäger, P. Schredl, D. Neureiter, M. Fallaha, J. Holzinger, M. Weitzendorfer, K. Emmanuel, A. Dinnewitzer (UK)

TRANSLATIONAL RESEARCH

I01

Effect of HIPEC on immune micro environment.

M.D. Ray (India)

I02

Prolonged hyperthermic intraperitoneal chemotherapy (HIPEC) can trigger a systemic inflammatory response. A study in humans.

L. Roth, D. Eshmuminov, F. Laminger, C. Koppitsch, M. Schneider, T. Reding Graf, K. Slankamenac, A. Gupta, F. Kober, S. Roka, P. Gertsch, K. Lehmann (Austria)

I03

Patient-derived organoids from colorectal peritoneal metastases as a platform for individualized hyperthermic intraperitoneal chemotherapy.

O. Kranenburg, I. Ubink, W.M. Van Grevenstein, S.G. Elias, I.H.M. Borel Rinkes (Netherlands)

I04

An in vitro model of HIPEC : facilitating pharmacological assessment in colorectal peritoneal metastases.

N. Un Nahar, U. Arshad, C. Goldring, P. Sutton (UK)

I05

Cytoreductive surgery and laparoscopy-enhanced hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis : four-years experience.

M. Lotti, G. Panyor, M. Marini, E. Vaterlini, M. Giulii Capponi, J. Silvas, C. Bertani, L. Campanati (Italy)

I06

Creation of a model of peritoneal carcinomatosis with pancreatic human cells for treatment with HIPEC.

E.P. García Santos, D. Padilla Valverde, P. Villarejo Campos, S. Sánchez García, J. Martín Fernández (Spain)

I07

Genetic lineage tracing of peritoneal mesothelial cells in a mouse model of peritoneal injury.

B. Wilm, P. Sutton, T. Wilm (UK)

I08

Synergistic apoptosis following endoplasmic reticulum stress aggravation in mucinous colon cancer.

H. Choudry, B. Honick, A. Dilly, Y. Lee, D. Bartlett (USA)

I09

The tumor suppressor gene cdx2 increases 5-fluorouracile resistance of colon cancer cells through THE ABCC11 transporter.

J.B. Delhorme, M.P. Chenard, E. Martin, J.N. Freund, S. Rohr, C. Brigand, I. Gross (France)

I10

HIPEC-induced alterations of peritoneal cellular immunity.

J. Franko, M. Andres (USA)

I11

Epithelial-mesenchymal transition markers in patients with peritoneal surface malignancies selected for cytoreductive surgery (crs) and hyperthermic intraperitoneal chemotherapy (HIPEC).

A. Sommariva, B. Montini, P. Del Bianco, V. Mozzo, S. Fasolato, M.A. Piano, C.R. Rossi, M.L. Calabrò (Italy)

I12

Non-canonical activation of the jak-stat pathway is potentially driven by activated inflammatory-related receptors in colorectal peritoneal carcinomatosis.

J. Hendrikson, X. Qiu, W.H. Ng, J.W.S. Tan, N.B. Shannon, C.S. Chia, G.H.C. Tan, K.C. Soo, O.L. Kon, C.A.J. Ong, M.C.C. Teo (Singapore)

I13

Novel organoid models to evaluate efficacy of immunotherapy for colorectal peritoneal metastases.

V. Narasimhan, T. Pham, M. Michael, A. Heriot, R. Ramsay (Australia)

I14

Precision medicine : development of a novel organoid based platform for personalised therapy in colorectal peritoneal metastases.

V. Narasimhan, T. Pham, M. Michael, R. Ramsay, A. Heriot (Australia)

I15

Variation of concentration of oxaliplatin in BSA based administration of oxaliplatin during HIPEC.

V. Verwaal, J. Funder, L. Iversen, M. Møller Sørensen (Denmark)

I16

Molecular and genetic markers in appendiceal mucinous neoplasms – a systematic review.

H. Mogal, A. Stein, T.C. Gamblin, C. Clarke, S. Tsai, J. Thomas, B. George (USA)

I17

CRS and oxaliplatin-based HIPEC in a rat model of colorectal peritoneal surface malignancy : establishing sensitivity and maximum tolerated dose in a validated assay.

L. Lemoine (Belgium), P. Sugarbaker (USA), K. Van Der Speeten (Belgium)

I18

KRAS and GNAS – druggable targets in pseudomyxoma peritonei ?

A.T. Kristensen, C. Lund-Andersen, L. Kyllingstad, Y. Andersson, I.S. Frøysnes, T.W. Abrahamsen, P. Krolokowski, I. Bergheim, B. Davidson, S. Dueland, S.G. Larsen, K. Flatmark (Norway)

I19

BRAF V600E mutation - a prognostic biomarker in peritoneal metastasis from colorectal cancer.

C. Lund-Andersen, A. Kristensen, L. Kyllingstad, I.S. Frøysnes, T.W. Abrahamsen, P. Krolowski, I. Bergheim, B. Davidson, S. Dueland, S.G. Larsen, K. Flatmark (Norway)

I20

Colorectal peritoneal organoids : establishment, validation and utility as a pre-clinical model of disease.

V. Narasimhan, T. Pham, A. Heriot, R. Ramsay (Australia)

I21

Characterization and consequences of hypogammaglobulinemia after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

C. Soldevila-Verdeguer, J.J. Segura-Sampedro, N. Esteve-Pérez, A. Craus-Miguel, Á. Molina-Fuentes, A. Repetto, M. Guillot-Morales, J. Milà-Llambí, J. Pons-De Ves, R. Morales-Soriano (Spain)

I22

Assessment of sensitivity of tumor tissue to cytotoxic drugs as an aid in the selection of an anticancer drug used in the HIPEC procedure.

T. Jastrzebski, H. Heidecke, T. Polec (Germany)

I23

Oxaliplatin tissular penetration during heated intraoperative chemotherapy (HIPEC) may impact survival.

O. Sgarbura, J. Bianga, M. Larroque, A. Bouslimani, N. Bec, C. Larroque, F. Quenet (France)

I24

A feasibility study of oxaliplatin + doxorrubicin administrated on the basis of concentration in the perfusate solution during HIPEC for the treatment of peritoneal metastases (PM).

P. Bretcha-Boix, V. Escudero, A. Catalan, M. Sureda, J. Farre-Alegre, M. Duarte, A. Paz, A. Brugarolas (Spain)

I25

Postoperative oxaliplatin in the biological fluids after heated intraperitoneal chemotherapy (HIPEC): a comparative study for procedures with and without lavage.

O. Sgarbura, M. Larroque, A.F. Villa, J. Poupon, C. Larroque, F. Quénet, M. Pocard, C. Eveno (France)

I26

Evaluation of natural killer (NK) and natural killer t (NKT) cell receptors in ovarian cancer.

S. Mehta, P. Kumar, J.M. Pramanik, J. Anam, P. Kammar (India)

I27

Comparison of experimental mouse models of colorectal peritoneal carcinomatosis.

A.T. Taibi, M.L.P. Perrin, L.C. Carr, C.Y. Yardin, P.L. Leveque, D.C.A. Arnaud Cormos, S.B.C. Bardet, S.D.F. Durand Fontanier (France)

I28

Nanosecond pulsed electric field (NSPEF) treatment for colorectal peritoneal carcinomatosis.

A.T. Taibi, M.L.P. Perrin, L.C. Carr, P.L. Leveque, C.Y. Yardin, D. Arnaud-Cormos, S.D.F. Durand Fontanier, S. Bardet (France)